Bayesian Variable Selection Methods for Genome-Wide Association Studies with Categorical Phenotypes by Rowe, Benazir
UNLV Theses, Dissertations, Professional Papers, and Capstones 
12-1-2020 
Bayesian Variable Selection Methods for Genome-Wide 
Association Studies with Categorical Phenotypes 
Benazir Rowe 
Follow this and additional works at: https://digitalscholarship.unlv.edu/thesesdissertations 
 Part of the Genetics Commons, Mathematics Commons, and the Statistics and Probability Commons 
Repository Citation 
Rowe, Benazir, "Bayesian Variable Selection Methods for Genome-Wide Association Studies with 
Categorical Phenotypes" (2020). UNLV Theses, Dissertations, Professional Papers, and Capstones. 4077. 
https://digitalscholarship.unlv.edu/thesesdissertations/4077 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by Digital 
Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Dissertation in any way that 
is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to 
obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons 
license in the record and/or on the work itself. 
 
This Dissertation has been accepted for inclusion in UNLV Theses, Dissertations, Professional Papers, and 
Capstones by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact 
digitalscholarship@unlv.edu. 
BAYESIAN VARIABLE SELECTION METHODS FOR GENOME-WIDE
ASSOCIATION STUDIES WITH CATEGORICAL PHENOTYPES
By
Benazir Rowe
Bachelor of Science - Mathematical Economics
Kyrgyz Russian Slavic University, Kyrgyzstan
2012
Master of Science - International Economics and Finance
Otto von Guericke University Magdeburg, Germany
2014
A dissertation submitted in partial fulfillment
of the requirements for the
Doctor of Philosophy - Mathematical Sciences
Department of Mathematical Sciences
College of Sciences
The Graduate College
University of Nevada, Las Vegas
December 2020






The Graduate College 
The University of Nevada, Las Vegas 
        
November 9, 2020
This dissertation prepared by  
Benazir Rowe 
entitled  
Bayesian Variable Selection Methods for Genome-Wide Association Studies with 
Categorical Phenotypes 
is approved in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy - Mathematical Sciences  
Department of Mathematical Sciences 
 
                
Amei Amei, Ph.D.       Kathryn Hausbeck Korgan, Ph.D. 
Examination Committee Chair      Graduate College Dean 
 
Malwane Ananda, Ph.D. 
Examination Committee Member 
        
Kaushik Ghosh, Ph.D. 
Examination Committee Member 
 
Guogen Shan, Ph.D. 
Graduate College Faculty Representative 
 
ABSTRACT
Bayesian Variable Selection Methods for Genome-wide
Association Studies with Categorical Phenotypes
by
Benazir Rowe
Dr. Amei Amei, Examination Committee Chair
Associate Professor of Mathematics
University of Nevada, Las Vegas, USA
Genome-wide association studies (GWAS) attempt to find the associations between genetic
markers and studied traits (phenotypes). The problem of GWAS is complex and various
methods have been developed to approach it. One of such methods is Bayesian variable
selection (BVS). We describe the BVS methods in detail and demonstrate the ability of
BVS method Posterior Inference via Model Averaging and Subset Selection (piMASS) to
improve the power of detecting phenotype-associated genetic loci, potentially leading to new
discoveries from existing data without increasing the sample size.
We present several ways to improve and extend the applicability of piMASS for GWAS.
The first method incorporates non-genetic covariates in the BVS process for GWAS with
continuous phenotype, therefore making it possible to account for population stratification.
Next, we extend the method mentioned above to work with binary phenotype. Finally,
iii
we extend the piMASS method to work with ordinal phenotype. The presented methods
allow the existing BVS methods reach wider applicability and higher quality of detected
associations. We conduct simulation studies and compare the results to the original method
piMASS to show their efficacy. We also apply two of the methods to the Alzheimer’s Disease
Neuroimaging Initiative 1 (ADNI1) dataset containing data on Alzheimer’s patients with
categorical phenotype and demonstrate the method’s ease of use and applicability. Finally,
we discuss the potential of the methods in GWAS and possible directions for further research.
iv
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In genetics, genome-wide association study (GWAS) is a method that aims at detecting
genomic loci associated with complex traits in the population, such as heart disease, dia-
betes, auto-immune diseases and psychiatric disorders [Visscher et al., 2012]. Typical GWAS
measures hundreds of thousands or millions of genetic variants in thousands or tens of thou-
sands of individuals. In situations where most of the regressors have no relationship to
the response, including all regressors in a regression model can lead to poor performance
[Hoff, 2009]. Therefore, only variables with evidence for association should be included in
the model, which gives not only a more concise and practical model, but also enhances model
prediction. Hence, the problem of GWAS is a variable selection problem.
Variable selection is one of the key aspects of the regression modelling, however, common ap-
proaches such as exhaustive search and stepwise procedures are prohibitive in GWAS context
due to large number of potential covariates. Bayesian approach offers a practical solution to
this issue: any collection of models with different sets of variables can be compared using
1
their Bayes factors. Bayes factor is a ratio of two likelihoods representing any two statistical
models and provides the summary of evidence provided by the data in favor of one scientific
theory, represented by a statistical model, as opposed to another [Kass and Raftery, 1995].
Bayesian variable selection (BVS) regression is a way to approach variable selection prob-
lem by specifying prior distributions on model parameters and calculating Bayes factors of
various models, which contain relevant information to perform the selection. In situations
where the number of variables is large, the space of possible models can be explored using
Markov chain Monte Carlo (MCMC) methods such as Metropolis-Hastings algorithm.
Another important feature of the GWAS is that effect sizes of genetic variants are often very
small and the total proportion of the variance of the response variable explained by covariates
is also small. Those features together require modification of the existing BVS methodology
to the problem in question. BVS is especially advantageous in GWAS context, since it can
handle large number of parameters and provides easily interpretable measures of confidence,
specifically posterior probability of a coefficient being nonzero for each variable included in
the model. It also allows modelling observable outcomes conditional on a set of parameters,
which themselves can be given a probabilistic specification in terms of further parameters,
known as hyperparameters [Gelman et al., 2013]. Data characteristics and dimensionality
play an important role in the specification of the BVS model.
In this chapter we first describe the existing methods in BVS. Next we focus on the posterior
inference via Model Averaging and Subset Selection (piMASS) [Guan and Stephens, 2011],
a BVS method with novel hyperparameter specifications tailored to the GWAS setting. In
2
presenting these methods we highlight their uses and motivate the models and methods pro-
posed in the upcoming chapters. At the end of the chapter, we provide an outline of the
dissertation.
1.2 Review of Bayesian variable selection
Below we present a general overview of BVS models. The goal of BVS is to choose relevant
covariates from a larger set of potential covariates, which is a subset selection problem.
Subset selection is often formulated in the context of multiple linear regression models.
Thus, the individual’s response yi is modelled using standard linear regression:
yi = µ+ xi1β1 + xi2β2 + ... + xipβp + εi, (1.1)
where yi is the response for i-th individual, µ is an intercept, xi1, ... , xip are covariates
measured on the ith individual, β1, ... , βp are the corresponding regression coefficients, and
εi is an error term. We assume that εis are independent and identically distributed with
εi ∼ N(0, σ2). The goal of this setup is to identify the relevant covariates among xi1, ... , xip
based on the evidence for association with the response yi.
Therefore, normal linear regression model may be used to describe the relationship between
the response y and potential covariates X1,X2, ... ,Xp, that is:
f(y | β, σ) ∼ Nn(µ+Xβ, σ2I), (1.2)
3
where y is a response vector of size n × 1, X = [X1, ... ,Xp] is an n × p matrix, where
Xj = (x1j, ... , xnj)
′ is a column vector containing the observed values of the jth covariate
at the n individuals, µ = µ×1, where 1 is a n× 1 vector of ones, β is a vector of regression
coefficients of size p× 1 and σ is positive scalar.
The problem of variable selection arises when one is uncertain about which predictors are
relevant to the outcome. Each of those possible 2p subsets is denoted using vector γ:
γ = (γ1, ... , γp)
′ ∈ {0, 1}p, (1.3)
where γi takes two values, 1 and 0, meaning covariate i is included in the model or not. The
size of the subset can be represented as dγ = γ
′
1, where 1 is a p × 1 vector of ones. Then
the possible models describing the relationship between response and the selected subset of
covariates are:
f(y | β,γ, σ) ∼ Nn(µ+Xγβγ , σ2I), (1.4)
where Xγ is an n× dγ matrix whose columns correspond to the design matrix X restricted
to the columns j for which γj = 1 and βγ denotes the corresponding regression coefficients.
Methods capable of avoiding the calculation of 2p possible models are essential in high
dimensional variable selection.
The joint prior on model parameters is [George and McCulloch, 1993]:
π(β, σ2,γ) = π(β|σ2,γ)π(σ2|γ)π(γ), (1.5)
where every part is further specified below.
4
First, we assume that γ components are independent, which means we expect that inclusion
of any variable in the model has no impact on whether any other variable should be included.




ωγii (1− ωi)(1−γi), (1.6)
which provides computational simplicity. Here π(γi = 1) = 1 − π(γi = 0) = ωi can be
interpreted as the prior probability that Xi is included in the model. Setting ωi to be small
will put increased weight on parsimonious models.
Second, variance of the residuals σ2 is assigned an inverse gamma prior distribution:
π(σ2 | γ) = IG(λ/2, k/2). (1.7)
While setting k to be constant leads to reasonable results [George and McCulloch, 1997],
it can be beneficial to have k decrease with the number of selected variables dγ . When
prior information about σ2 is scarce, it is recommended to choose k and λ so that prior
assigns substantial probability to the interval between the least squares estimate based on a
saturated model and the sample variance of y.
Finally, the vector of regression coefficients β is assigned a multivariate normal prior
[George and McCulloch, 1993]:
π(β | σ,γ) = Np(0,W(σ,γ)), (1.8)
where 0 is an p-vector of zeros and W(σ,γ) is the p-dimensional covariance matrix where the
ith diagonal element is appropriately set to be large or small based on whether γi = 1 or 0.
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Specification of W(σ,γ) determines the key properties of the specified hierarchical prior. The
effect of this specification for the variable selection are of particular importance and should
reflect the properties of the specific context in which the selection is performed.
For example, consider the following conjugate specification of W(σ,γ):
π(β | σ,γ) = Np(0, σ2DγRγDγ), (1.9)
where σ2 is the variance of the residuals, Dγ is a diagonal matrix, where each diagonal
element of Dγ contains the corresponding standard deviation of the corresponding compo-
nent of vector β, i.e. (Dγ)ii = sd(βi), i = 1, ... , n and Rγ is a correlation matrix of β.
One simple choice for the correlation matrix is Rγ = I, making components of β uncor-
related. Other possible choice is Rγ = (X
′
γXγ)
−1, replicating the correlation structure of
least squares estimate.
The ith diagonal element of D2γ representing the variance of β coefficients is denoted by
(D2γ)ii =
{
ν0, if γi = 0,
ν1, if γi = 1.
(1.10)
Under (1.10) each component of β is assumed to be a weighted sum of two normal distribu-
tions, sometimes called a scaled mixture of normals:
π(βi | σ,γ) = (1− γi)N(0, σ2ν0) + γiN(0, σ2ν1). (1.11)
It is therefore convenient to present the conditional prior for β as
βγ |σ2,γ ∼ Ndγ (0, σ2ν1Idγ ), (1.12)
β−γ |γ ∼ Nn−dγ (0, σ2ν0In−dγ ), (1.13)
6
where βγ denotes a vector of regression coefficients corresponding to elements ofX for which
γj = 1 and β−γ denotes the vector of β coefficients for which γj = 0.
Since conditional distribution of β and σ given γ is conjugate for (1.4)
[George and McCulloch, 1993], the resulting hierarchical mixture prior can be called con-
jugate prior, so β and σ can be eliminated by routine integration from the full posterior
π(β, σ,γ|y). This gives convenient computational methods for posterior evaluation.
When ν0 ≡ 0 combining the likelihood from (1.4) with the priors (1.6)-(1.9) and (1.12)-(1.13)
gives the joint posterior:
π(β,γ, σ|y) ∝ σ(n+dγ+λ+1)/2
∣∣∣DγRγDγ∣∣∣−1/2 exp(− 1
2σ2


















With the setup provided above, the marginal posterior distribution π(γ|y) carries the infor-
mation to conduct the variable selection. Based on response data y, the posterior distribution
π(γ|y) identifies the models better supported by the prior distributions and the data. The
ability of the above setup to correctly select the associated variables in a reasonable amount
of time depends on a few factors. One, parameters of the prior must be set in a way that
posterior distribution π(γ|y) will assign higher probability to the subsets of covariates that
are of interest for a given problem [George and McCulloch, 1997]. Next, since π(γ|y) is not
always available in closed form, it is necessary to be able to compute π(γ|y) at least to the
7
extent it is possible to differentiate between γi = 0 and γi = 1 for each γi. Hyperparameters
allow to set important characteristics of the model, such as model sparsity and proportion
of the variance in the response variable explained by the covariates. The next section intro-
duces a BVS model with priors on hyperparameters tailored to the GWAS.
1.3 piMASS and its novel prior on variance component
The ability to specify priors is an important feature of Bayesian approach, since it helps to
focus on a particular subset of parameters and saves important computation time explor-
ing regions of parameter space that are less plausible. Such priors have been proposed
for continuous and binary response variables in a linear model in the method piMASS
[Guan and Stephens, 2011]. The novel prior on the variance of regression coefficients is what
sets piMASS apart from the previous work done in the area of BVS. We chose piMASS as our
base BVS method because of its GWAS -tailored prior structure and feasible computational
properties.




xijβj + εi, (1.15)
where yi is a response of the i-th subject, µ is an intercept, xij is a j-th covariate of i-th
subject, βjs are the corresponding regression coefficients and εi is an error term. εi are
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independent and identically distributed εi ∼ N(0, 1/τ), where τ denotes the inverse of the
variance, often referred to as precision.
Thus the distribution of the response is:
y|γ,µ, τ,β,X ∼ Nn(µ+Xβ, τ−1In), (1.16)
relating the response variable y to covariates X. In the context of GWAS the response y
is the phenotype (observable and measurable characteristic) under investigation for each of
the n study subjects. Next, X is an n × p matrix of covariates , where xij is the genotype
of subject i at the genetic variant or single nucleotide polymorphism (SNP) j and xij = 0, 1
or 2 depending on whether the subject has 0, 1 or 2 copies of the minor allele. In model
(1.16) µ is an n-vector with each component equal to the same scalar µ, β is a p-vector of
regression coefficients and τ is the inverse variance of the residual errors.
The binary indicators denoted as γ and defined in (1.3) show which elements of β are
nonzero. Then the model becomes:
y|γ,µ, τ,β,X ∼ Nn(µ+Xγβγ , τ−1In), (1.17)
where Xγ denotes the design matrix X restricted to those columns j for which γj = 1 and
βγ denotes a corresponding vector of regression coefficients. The setup above follows the
standard setup for the hierarchical mixture model for variable selection and allows to account
9
for sparsity that is inherent to GWAS. Next, the priors on model parameters:
τ ∼ Gamma(λ/2, k/2) (1.18)
µ|τ ∼ N(0, σ2µ/τ) (1.19)
γj ∼ Bernoulli(π) (1.20)
βγ |τ,γ ∼ Ndγ (0 , (σ2a/τ) Idγ ) (1.21)
β−γ |γ ∼ δ0, (1.22)
where δ0 is a point mass at 0 and λ, k, σµ, π and σa are hyperparameters. Hyperparameters
π, which reflects the model sparsity and σa, which reflects the typical size of a nonzero
regression coefficients are playing important roles in tailoring model to GWAS. Therefore,
instead of being assigned fixed values, in piMASS they get their own prior distributions.
Other hyperparameters are less critical and in practice λ, k → 0 and both response vector y
and covariates X1, ... ,Xp are centered to have mean 0, setting µ = 0.
Equations (1.21) and (1.22) give
π(βi | γi) = (1− γi)δ0 + γiN(0, (σ2a/τ). (1.23)
Since (1.23) contains the mixture of a normal distribution and a point mass at 0, any βi 6= 0
will be included in the model. This is different compared to (1.11), where the mixture prior
for β contains two normal distributions with different variances, in which case covariates
with larger βi are selected. In contrast, (1.23) will lead to selection based on how different
βi is from 0 rather than the absolute size of the βi. This property is desirable for GWAS
since effect sizes of SNPs are often small, yet still valuable.
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Additionally, the specification of π(β|γ) requires the choice of a prior correlation matrix Rγ .
Here Rγ = I, setting the components of β to be independent, which allows for rapid update
of the posterior if γ is changed one component at a time [George and McCulloch, 1993].
The prior on π is specified in the following way:
log(π) ∼ U(a, b) (1.24)
where a = log(1/p) and b = log(M/p), so the lower and upper limits of π correspond to the
models which are expected to include between 1 and M variables.
The novelty of piMASS is in nonstandard prior on variance component σa. The motivation
behind the formulation is that in piMASS, priors on variance component translate assump-
tions about the the expected proportion of the variance in y explained by Xγ (PVE). The
main idea here is to choose a prior on β given τ so that induced prior on PVE is approxi-
mately uniform on (0, 1).
In more detail, let V (β, τ) denote the empirical variance of Xβ relative to the residual
variance τ−1:
















Equation (1.25) assumes covariatesX have been centered, setting µ = 0. Next, let PV E(β, τ)
be the total proportion of variance in y explained by X if the true values of regression co-
11
efficients are β:





















V (β, τ) + 1
.
(1.26)
Define v(γ, σa) = E(V (β, τ)) . Then σa is connected to V (β, τ) through its expectation
E(V (β, τ)) in the following way:










































In piMASS, h is defined as:
h(γ, σa) =
v(γ, σa)
v(γ, σa) + 1
, (1.28)
where h denotes the approximation to the expectation of the PV E(β, τ ) for given values of
γ and σa:
E(PV E(β, τ)) = E
( V (β, τ)
V (β, τ) + 1
)
≈ E(V (β, τ))
E(V (β, τ) + 1)
=
v(γ, σa)
v(γ, σa) + 1
. (1.29)
Here h is not exactly the expectation of the PV E(β, τ ), but instead a ratio of expectations
of its numerator and denominator.
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Combining (1.27) and (1.28) and specifying a uniform prior on h, independent of γ, an





























Here the priors are specified and the inference is performed in terms of (h,γ) rather than
(σa,γ). Note that induced prior on σ
2
a is noninformative.
piMASS follows the linear model described in the previous section, except it offers a novel
treatment of the prior on hyperparameter σa by connecting it to the PVE. The uniform
prior on h suggests that the number of relevant variables is no longer necessarily positively
correlated to the proportion of variance explained by them. Such prior structure is proper
for the situation where there are many relevant variables, with each having tiny effect and
overall proportion of variability explained by relevant covariates is small. This property of
piMASS matches the genetic architecture of many common diseases, where many loci, each
with a very small effect, collectively contribute to the disease.
To successfully perform variable selection in GWAS context, it is potentially beneficial to in-
clude variables accounting for population structure [Kärkkäinen and Sillanpää, 2012], which
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do not necessarily follow the same distribution as the one specified above for X. Including
population structure covariates is especially important since they often contribute to spuri-
ous associations between genetic variants and the phenotype, which can lead to the selection
of irrelevant covariates. While for piMASS, it is possible to account for population structure
covariates when phenotype is continuous, when phenotype is categorical there is no obvious
way to do it. Therefore, it is potentially beneficial to develop a BVS method that both
includes population structure variables and works for categorical data. In the next chapters
we focus on extending piMASS to include population structure variables first for continuous,
then for binary and ordinal categorical phenotypes.
1.3.1 MCMC scheme for piMASS
The likelihood function of the model in (1.17) is:




(y −Xγβγ)T (y −Xγβγ)
)
. (1.32)
MCMC is used to sample from the joint posterior distribution of (h, π,γ), which is given by
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Here p(y|h, π,γ) = p(y|h,γ) since hyperparameter π affects y only through γ, and p(h, |π,γ) =
p(h) since π,γ do not affect h. Parameters β, τ can be integrated out to compute the
marginal likelihood p(y|h,γ).
Since piMASS follows conjugate hierarchical prior setup, it allows β and σ to be integrated
out analytically to compute p(y|h,γ) [Servin and Stephens, 2007]. The Bayes factor is:
p(y | h,γ)
p(y | h,γ = 0)
= n1/2 | Ω |1/2 1
σa(h,γ)|γ|











and 0 denotes a p-vector of all zeros. For each
sampled value of h,γ from the posterior, β and τ are obtained by sampling from their
conditional distributions given y,γ, h:




yty − ytXγΩX tγy
))
, (1.35)
βγ |τ, h,γ ∼ N(ΩX tγy, (1/τ) Ω), (1.36)
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β−γ |τ,y, h, γ ∼ δ0. (1.37)
MCMC algorithm is based on Metropolis-Hastings algorithm, using a simple local proposal
to jointly update h, π,γ with more details in [Guan and Stephens, 2011].
1.4 Outline of the dissertation
While piMASS is a powerful BVS method for GWAS, we identified several ways to improve it,
with the novel methods for GWAS analysis in Bayesian framework described in the following
chapters. The dissertation is organized as follows.
Chapter 1 contains the review of BVS methods. In particular, we focus on BVS method
piMASS, developed specifically for genetic data, which is central to the current dissertation
and methodology proposed in later chapters.
Chapter 2 contains the application of the material presented in Chapter 1 to binary pheno-
type data, which resulted in a publication [Rowe et al., 2019] in the journal npj Schizophrenia
on November 19, 2019. The work was co-authored with Xiangning Chen (Nevada Institute
of Personalized Medicine, University of Nevada, Las Vegas, NV, USA), Zuoheng Wang (De-
partment of Biostatistics, Yale School of Public Health, New Haven, CT, USA), Jingchun
Chen (Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, NV,
USA) and Amei Amei (Department of Mathematical Sciences, University of Nevada, Las
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Vegas, NV, USA).
We applied piMASS to the molecular genetics of schizophrenia (MGS) data set with 5, 334
subjects and compared the results with the previous univariate analysis of the MGS data
set. The results showed that piMASS can improve the power of detecting schizophrenia-
associated SNPs, potentially leading to new discoveries from existing data without increasing
the sample size.
In Chapter 3 we consider a Bayesian approach to incorporate non-genetic covariates that
account for confounding factors such as population structure for continuous phenotypes.
We include such covariates in the model by specifying priors on them and using them in
variable selection process. We run a simulation study to investigate the performance of the
proposed model by comparing the extended model to the model without population structure
correction. In our simulations, we use two sets of genotype data. First set of genotype data
is simulated using package COSI2 [Shlyakhter et al., 2014]. Second set of genotype data is a
subset of the publicly available MGS data set. We investigate the properties of the extended
model using both sets of genotype data. In conclusion, we discuss the accomplishments and
limitations of the proposed method.
In Chapter 4, we present a model accounting for population structure covariates with binary
phenotypes. We conduct simulations assessing the model’s performance. We discuss the
model’s performance and applicability, as well as its limitations. In addition, we conduct
real data analysis and discuss its results.
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In Chapter 5 we provide the extension of piMASS to work with ordinal phenotype data with
more than two categories, which can significantly expand its applicability to a wider range of
existing data sets. Theoretical foundations, practical application as well as real data analysis
are provided in this chapter.
Chapter 6 discusses the BVS and its applications presented in Chapters 1 and 2 and sum-
marizes the methods proposed in Chapters 3, 4 and 5 for the Bayesian analysis of GWAS
and discusses the directions for future research.
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CHAPTER 2
GENOME-WIDE ASSOCIATION STUDY OF
SCHIZOPHRENIA USING BAYESIAN VARIABLE
SELECTION
2.1 Introduction
In this chapter we present the GWAS of schizophrenia we conducted using BVS method
piMASS. The material of this chapter is based on the publication “Biological and practi-
cal implications of genome-wide association study of schizophrenia using Bayesian variable
selection” [Rowe et al., 2019] in the journal npj Schizophrenia on November 19, 2019. The
work was co-authored with Xiangning Chen (Nevada Institute of Personalized Medicine, Uni-
versity of Nevada, Las Vegas, NV, USA), Zuoheng Wang (Department of Biostatistics, Yale
School of Public Health, New Haven, CT, USA), Jingchun Chen (Nevada Institute of Person-
alized Medicine, University of Nevada, Las Vegas, NV, USA) and Amei Amei (Department
of Mathematical Sciences, University of Nevada, Las Vegas, NV, USA).
To date GWAS have identified over 100 loci associated with schizophrenia. Most of these
studies test genetic variants for association one at a time. In this chapter, we show GWAS
of the MGS dataset with 5, 334 subjects using multivariate BVS method piMASS and com-
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parison of our results with the previous univariate analysis of the MGS dataset. We showed
that piMASS can improve the power of detecting schizophrenia-associated SNPs, potentially
leading to new discoveries from existing data without increasing the sample size. We tested
SNPs in groups to allow for local additive effects and used permutation test to determine
statistical significance in order to compare our results with univariate method. The previ-
ous univariate analysis of the MGS dataset revealed no genome-wide significant loci. Using
the same dataset, we identified a single region that exceeded the genome-wide significance.
The result was replicated using an independent Swedish Schizophrenia Case-Control Study
(SSCCS) dataset. Based on the SchiZophrenia Gene Resource database 2.0 (SZGR 2.0),
we found 63 SNPs from the best performing regions that are mapped to 27 genes known
to be associated with schizophrenia. Overall, we demonstrated that piMASS could discover
association signals that otherwise would need a much larger sample size. Our study has
important implication that reanalyzing published datasets with BVS methods like piMASS
might have more power to discover new risk variants for many diseases without new sample
collection, ascertainment, and genotyping.
2.2 Background
Schizophrenia is a severe psychiatric disorder with an estimated global lifetime prevalence
of 0.4 − 0.75% with no significant differences across urban, rural, and mixed sites or gen-
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ders [Saha et al., 2005], [Moreno-Küstner et al., 2018]. While being a low prevalence dis-
order, it has substantial societal burden [Charlson et al., 2018]. The estimated heritability
of schizophrenia ranges from 70 to 90% [Sullivan et al., 2003]. The common susceptibility
variants of such disease are typically identified by association studies, such as genome-wide
association studies. In these studies, SNPs are often tested one at a time. In recent years,
genetic studies of schizophrenia have made substantial progress. Since the report of the ma-
jor histocompatibility complex (MHC) locus on chromosome 6 in 2009 [Shi et al., 2009], the
number of schizophrenia-associated genetic loci has risen to 5 loci in 2011 [Ripke et al., 2011]
and to 108 loci in 2014 [Ripke et al., 2014]. This increase in the number of significant loci
could be partially explained by the increase in the sample size of the studies that led to
improvement in the statistical power of the association tests. However, these studies also
suggest that common variants usually have small to medium effects that makes them hard
to reach the typical GWAS significance threshold (P = 5× 10−8). The application of regres-
sion methods on set of genetic variants with appropriate prior specification may have the
potential to uncover the largely hidden heritability.
It is well known that the single-SNP approach has its advantage in its simplicity of use, well-
established pipeline and low computational burden. However, one of the major drawbacks is
that it may miss some potential additive effects derived from sets of SNPs or genes. Methods
like Bayesian variable selection take these considerations into account and analyze multiple
loci simultaneously. For diseases with complex genetic architecture, such as schizophre-
nia, it is possible that BVS combined with powerful computing resources might be supe-
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rior to single-SNP approach. Indeed, Bayesian methods have demonstrated their abilities in
search for genetic risk factors in schizophrenia and other complex disorders [Hall et al., 2007],
[Baragatti et al., 2011], [Carbonetto et al., 2012]. Since then, much have been developed in
the area of Bayesian GWAS [Servin and Stephens, 2007], [Logsdon et al., 2010]. The pi-
MASS algorithm is one of such examples [Guan and Stephens, 2011]. It offers a BVS pro-
cedure that is designed for continuous phenotypes with an extension to binary phenotypes
using a probit link function. By considering a set of genetic variants, piMASS extracts more
information beyond the marginal associations in standard single-SNP analyses while main-
taining reasonable computation time [Guan and Stephens, 2011]. Therefore, piMASS has
potential to uncover more associations through reanalysis of existing GWAS datasets.
In this study, we chose a dataset with a moderate sample size, MGS that has previously
been analyzed using univariate methods [Shi et al., 2009] and reanalyzed the dataset using
piMASS. We hypothesize that piMASS can discover more associations when applied to MGS
dataset compared with the single-SNP methodology used in [Shi et al., 2009]. Specifically,
we use piMASS to evaluate associations of a set of genetic variants in a moderate sample
size of 5, 334 subjects (2, 681 cases and 2, 653 controls) with binary phenotype using Pos-
terior Inclusion Probabilities (PIPs) - measures of confidence that individual variants have
nonzero effects, no interaction effects considered. Such direct comparison with one of the
most common GWAS methods can shed the light on the utility of piMASS in analysis of
moderate size datasets. We used permutation test to validate our findings with an indepen-
dent schizophrenia case-control dataset of similar size (2, 895 cases and 3, 836 controls). Our
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results indicate that compared with single-SNP approaches, BVS method, such as piMASS,
could discover association signals with a relatively small sample size that might have been
undetectable by single-SNP approaches.
2.3 Methods
2.3.1 GWAS datasets
In discovery, we performed association analysis using the MGS study (n = 5, 334) that
consists of 2, 681 schizophrenia cases and 2, 653 healthy controls of European ancestry. De-
tails of the dataset have previously been described [Shi et al., 2009]. In validation, we chose
batches 5 and 6 of the SSCCS dataset (n = 6, 731), including 2, 895 cases and 3, 836 controls
[Ripke et al., 2011].
Both MGS and SSCCS GWAS datasets were downloaded from NIMH Genetic Repository and
Resource (https://www.nimhgenetics.org/) upon approval. The genotypes were down-
loaded from NIMH without further quality check because the genotypes from NIMH were
checked and met the standard requirement of NIMH. The two datasets were genotyped us-
ing different platforms: the MGS was genotyped using the Affymetrix 6.0 chip that includes
638, 937 SNPs, and the batches 5 and 6 of the SSCCS were genotyped using the Illumina
OmniExpress chip that includes 646, 699 SNPs. In this work, we did not do any SNP an-
notation as both datasets are using GRCh37/hg19 as the human reference genome. While
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the SSCCS dataset has more subjects, its order of magnitude is approximately the same as
of MGS (5, 334 subjects with 638, 937 SNPs in MGS vs. 6, 731 subjects with 646, 699 SNPs
in SSCCS) in a sense that we expect both datasets to have similar power in detecting the
associations.
The genotype of an individual is coded as 0, 1, or 2 whether the subject has 0, 1, or 2 copies
of the minor allele. Missing genotypes were replaced by the sample average of the genotypes
at the position where the genotype is missing. Phenotypes were recorded as a binary variable
indicating presence or absence of a schizophrenia diagnosis.
2.3.2 Study design
The objective of the current study is to evaluate whether piMASS can improve the detection
of association signals as compared with standard univariate procedure. To this end, we chose
a dataset with a moderate sample size that has previously been analyzed using univariate
methods [Shi et al., 2009]. We did not perform genotype imputation and used the same
set of markers as in the study [Shi et al., 2009]. Guan and Stephens mention that BVS
regression tends to spread the association signal (the PIPs) among the correlated SNPs
[Guan and Stephens, 2011]. Therefore, to apply piMASS, we partitioned the genome-wide
data into smaller regions to capture additive effects of neighboring SNPs. Based on our
computational resources, we set 1, 000 SNPs as the region in a single run. Given that we
did not impute genotypes, it was more practical to proceed with regions containing equal
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number of SNPs. Since piMASS searches for various model configurations by proposing to
add, remove, and switch covariates in the model, we used a sliding window approach in which
each chromosome was cut into regions of 1, 000 SNPs with the overlap of 500 SNPs. This
ensures that piMASS has the opportunity to explore models containing all nearby SNPs.
This approach produced 1, 266 regions in the MGS dataset. A typical region spans around
37 million base pairs.
We tested each region for association with phenotype using piMASS by performing MCMC
runs with one million iterations each. The convergence of the 2 parallel MCMC runs was
confirmed by the Gelman-Rubin statistic being < 1.04. We did not include covariates to
correct for potential population stratification since it has been noted in the literature that
Bayesian regression models simultaneously fitting multiple SNPs are robust for population
stratification [Kärkkäinen and Sillanpää, 2012]. To distinguish SNPs with the strongest ev-
idence of association, we use PIP for each SNP. Since nearby SNPs are usually correlated
and the PIPs can spread around correlated SNPs, it is possible that none of the single SNPs
in the region have high PIP but the sum of PIPs would be high indicating the posterior
probability of at least one of the SNPs should be included in the model. The design of
combining multiple loci into a region helps better explore all possible models. Given that
the regions are defined in terms of fixed number of SNPs, we used the sum of PIPs as the
main measurement of association following analysis [Guan and Stephens, 2011].
piMASS allows user to input parameters (priors) appropriate for the specific question in a
GWAS and therefore utilize the existing domain knowledge. From the latest GWASs, it is
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known that more than 100 genetic loci are associated with schizophrenia, but each locus has
very small effect [Shi et al., 2009], [Ripke et al., 2011], [Ripke et al., 2014]. This knowledge
can be utilized to specify the ranges of the prior parameters. In the model, we specified the
following two parameters: the proportion of the phenotypic variance explained by relevant
variants and the proportion of SNPs that we expect to be relevant to the phenotype. The
first parameter represents the estimate of overall signal in the genotype data, e.g., how much
variation in the diagnosis can be explained by the SNP data. We set a prior on this quantity
to be uniformly distributed from 0.01% to 1% according to the two previous schizophrenia
studies [Ripke et al., 2014], [Lee et al., 2012]. These two studies suggest that the variants
across the genome collectively explain 18-23% of phenotype variation [Ripke et al., 2014],
[Lee et al., 2012]. But for each variant, the variation explained is very small. Ripke et al.
[Ripke et al., 2011] found 108 variants, the expected proportion explained by a single variant
would be 0.184/108 = 0.0017, which falls in the range we used as a priori information in
the model. The prior on the second parameter was set in such a way that the expected
number of SNPs that are relevant to the phenotype ranges from 1 to 5 loci in each region
containing a group of 1, 000 SNPs. One could also set restriction on the total number of
SNPs to be allowed in the model. In this study, we set it to 5 SNPs due to computation
time considerations.
The key feature of prior setting in piMASS is that the number of relevant variables is no
longer necessarily positively correlated to the proportion of variance explained by them. Such
prior structure is proper for the situation where there are many relevant variables, each has
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tiny effect and overall proportion of variability explained by relevant covariates is still small.
This feature of piMASS matches the genetic architecture of schizophrenia where many loci,
each with a very small effect, collectively contribute to the disease.
In the initial application of piMASS to the MGS dataset, sum of PIPs for the 1, 266 regions
in the MGS dataset did not show clear separations (Fig. 2.1). The sum of the PIP for
each region varies, yet there are no outstanding spikes that can be seen from the graph.
Therefore, it was not clear which regions contain SNPs that are associated with the trait.
We borrowed frequentist permutation test to determine an appropriate significance threshold,
which would make our results comparable with those reported previously [Shi et al., 2009].
We used empirical method based on the Fishers concept of a permutation test. Given
that 1266 overlapping regions were tested simultaneously, it was necessary to correct the
significance threshold for multiple comparisons. We chose Bonferroni correction for this
purpose. Since our focus is on gene discovery, we set α = 0.1, being more liberal than
the traditional 5% level to compensate for the well-known conservativeness of Bonferroni
multiple correction. Although the larger may produce more false positives, we expect to







≈ 7.9×10−5 was further validated using an independent dataset. The
target number of permutations was set to 100, 000. To save computation time, we stopped

















Figure 2.1: piMASS genome-wide region-based performance of the MGS dataset. The sum
of posterior inclusion probabilities (PIPs) for each of the 1, 266 overlapping regions spanning
22 chromosomes of the MGS dataset
2.3.3 Validation
The main goal of validation is to check if the results obtained using piMASS could be
replicated in an independent dataset so that the method could be applied to discover new
loci in general. Several regions in the discovery dataset that performed best in terms of the
empirical p-values from the permutation were tested and verified using an independently
collected dataset (SSCCS dataset) with similar sample size. As mentioned above, the two
datasets were genotyped using different platforms with different sets of SNPs. As we only
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included the SNPs that belong to the region with the same position interval, the number of
SNPs in each validation region is not exactly 1, 000. Accordingly, the mean of PIPs is used as
a measure of association to account for the variable number of markers in the discovery and
the corresponding validation regions. We use α = 0.05 and correct for multiple comparisons
based on the number of regions undergoing the validation. This yields empirical p-value
based on 1, 000 permutations for each validation region.
Since the best performing regions based on the permutation test are in the top 2% of all
regions according to the initial run using the MGS dataset, we also conducted the separate
piMASS analysis of SSCCS dataset with no permutation test, followed by an overlap analysis
of both datasets based on piMASS results without permutation test. In detail, top 5% of the
best performing regions based on sum of PIPs were selected. For each such region, top 1%
of the best performing SNPs based on PIPs were selected, comprising a table of SNPs with
the highest PIP among regions with the highest sum of PIPs for each dataset. We checked
every SNP in each table if it is within 100, 000 base pairs (bp) distance of SNPs from the
other dataset. Those SNPs comprise overlap set between the two datasets. Next, for each
pair in the overlap set we checked LD between the SNPs in the pair. If two SNPs were in
LD, they were considered in the consensus set. The larger size of the consensus set points
toward consistency of the piMASS method.
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2.4 Results
In the discovery dataset MGS, region 29 on chromosome 15 containing SNPs between
83, 907, 801 and 86, 887, 657 reached genome-wide significance after Bonferroni correction
(Rank 1, Pdisc = 1.43 × 10−5, Pvali = 0.001). rs16940789, rs16941261, rs4887364, rs991728,
rs2114252, and rs994068 are among the SNPs with top 1% highest PIP and mapped to
gene NTRK3 in the SchiZophrenia Gene Resource database, SZGR 2.0 (https://bioinfo.
uth.edu/SZGR/), a comprehensive database of variants and genes reported to have an as-
sociation with schizophrenia [Jia et al., 2017]. NTRK3 has been shown to be associated
with bipolar and other psychiatric disorders [Nurnberger et al., 2014], [Forstner et al., 2014],
[Verma et al., 2008]. The gene encodes a member of the neurotrophic tyrosine receptor ki-
nase (NTRK ) family, which is involved in the nervous system. rs16940789 was also mapped
to gene LINC00052 (an RNA gene that is affiliated with the noncoding RNA). The locus
had not been previously reported in refs [Ripke et al., 2014], [Ruderfer et al., 2019].
Although only one locus surpassed Bonferroni correction (Pdisc < 7.9× 10−5), some regions
with the empirical p-value (Pdisc) that are close to the cutoff might still be of interest because
Bonferroni correction is known to be too conservative. We used a design of sliding window
with overlapping SNPs. Table 1 lists 12 regions with the best association metric (Pdisc) based
on 100, 000 permutations using the MGS dataset, as well as their corresponding empirical
p-values based on 1000 permutations using the SSCCS dataset (Pvali). For each of the 12
regions reported in Table 1, we ranked the 1000 SNPs in terms of the PIP generated from
the initial run using the MGS dataset and listed the top ten SNPs based on PIP within each
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region. The Manhattan plot of the PIP of individual SNP from the initial run using the
MGS dataset is shown in Fig. 2.2 using − log10 (1− PIP) as the y-axis.
Chr Region a Start positionb End positionb Rankc Pdisc
d Pvali
e
15 29 83,907,801 86,887,657 1 1.43E-05 0.001
19 5 15,724,023 22,638,628 2 1.67E-04 <0.001
14 33 86,399,092 90,573,122 3 2.20E-04 <0.001
9 24 34,905,605 70,379,322 4 2.50E-04 0.002
14 6 29,288,170 33,177,081 5 3.00E-04 <0.001
8 30 53,113,091 57,376,926 5 3.00E-04 0.001
20 1 9795 2,715,620 7 3.33E-04 <0.001
18 15 28,642,588 33,646,071 8 5.00E-04 <0.001
15 28 80,260,648 85,190,202 9 5.50E-04 <0.001
1 36 81,955,643 85,727,849 10 5.67E-04 <0.001
13 41 98,395,342 101,641,945 11 6.00E-04 <0.001
3 15 22,010,347 25,354,138 12 7.50E-04 0.001
Table 2.1: Regions with best association metrics (Pdisc) based on permuta-
tion test
a Regions were assigned separately to each chromosome starting from 1
b Start position reflects the position of the first SNP included in the region,
end position reflects the position of the last SNP included in the region
c Rank is based on empirical p-value calculated from permutation test using
the MGS dataset
d Empirical p-value based on 100, 000 or less permutations using the discov-
ery dataset (MGS)
e Empirical p-value based on 1, 000 permutations using the validation dataset
(SSCCS)
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Figure 2.2: Manhattan plot of 1-PIP for the MGS dataset
Among the top 1% of the SNPs of the validated best performing regions in permuta-
tion test, there are 5 SNPs that have been mapped to genes associated with schizophre-
nia in the GWAS Catalog [MacArthur et al., 2017] (Table 2). Average C-scores based
on Combined Annotation-Dependent Depletion (CADD) method are also listed in Table
2 [Kircher et al., 2014]. SNPs rs993804 and rs4858697, located at 3p24.2, are in Link-
age Disequilibrium (LD) (R2 = 0.45) and are mapped to the gene AC092422.1 (RARB)
(chr3:24687919-25174305). AC092422.1 (RARB) had been reported to be associated with
schizophrenia and bipolar disorder in a meta-analysis for genome-wide association data us-
ing European-American samples [Wang et al., 2010]. SNP rs2044117, located at 13q32.3, is
mapped to genes NALCN-AS1 and NALCN. NALCN-AS1 was reported to be associated
with schizophrenia and bipolar disorder [Wang et al., 2010]. The NALCN was reported to
be associated with multiple traits including bipolar disorder, eating disorder, schizophre-
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nia, adolescent idiopathic scoliosis, HIV-associated dementia, psychosis, recurrent major
depressive disorder, etc. [Hall et al., 2018], [Kanazawa et al., 2013], [Levine et al., 2012],
[Liu et al., 2018], [Liu et al., 2016]. SNP rs9554752 is also mapped to NALCN and it is
in LD with rs2044117 (R2 = 0.11). SNP rs915071, located at 14q12, is mapped to genes
AL352984.2: LOC105370439 and LOC105370440 that were reported to be associated with
schizophrenia and bipolar disorder [Wang et al., 2010]. The CADD scores for SNPs in Table
2 range from 0.898 to 9.444. Resulting CADD scores point to the fact that piMASS alone
cannot discover causal variants. The main reason is that piMASS is a tool for association
testing, and hence the SNPs discovered are not necessarily causal. Moreover, other study
characteristics like region-based design and unimputed dataset add to the fact that addi-
tional steps may be necessary to investigate the pinpointed regions for causal SNPs.
Chr Gene Region SNP Positiona MAFb PIP C-scorec
3 AC092422.1 (RARB) rs993804 25,070,680 0.27 0.059 5.917
3 AC092422.1 (RARB) rs4858697 25,075,091 0.46 0.044 2.97
13 NALCN, NALCN-AS1 rs2044117 101,055,958 0.13 0.124 9.444
13 NALCN rs9554752 101,073,961 0.35 0.040 1.960
14 LOC105370439,LOC105370440 rs915071 31,964,652 0.40 0.738 0.898
a Position is referred to NHGRI-EBI GWAS Catalog
b Minor allele frequency (MAF) in the 1, 000 Genomes Phase 3 combined population
c Average C-score based on Combined AnnotationDependent Depletion (CADD) method
Table 2.2: SNPs with their mapped genes
Based on the permutation test on the discovery dataset, region 5 on chromosome 19 has
the second smallest empirical p-value (Rank 2, Pdisc = 1.67 × 10−4, Pvali ≤ 0.001. Among
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the SNPs having the highest 1% PIPs within this region, there are six SNPs (rs2965189,
rs2916074, rs4808200, rs4808203, rs4808964, and rs10419912) and they are in high LD
(R2 ≥ 0.93) with rs2905426 located at 19p13.11. The SNP rs2905426 is a variant be-
longing to a regulatory region of genes GATAD2A and MAU2. This variant was previously
reported to be associated with schizophrenia from the Psychiatric Genomic Consortium
(PGC) study, where 128 independent associations with 108 conservatively defined loci were
identified in a GWAS of up to 36, 989 cases and 113, 075 controls [Ripke et al., 2014] (see
also refs [Lieberman et al., 2005], [Hindorff et al., 2009], [Sullivan et al., 2012]). Based on
SZGR 2.0, we found 63 SNPs out of the 120 SNPs that are mapped to 27 genes in the SZGR
2.0 database and shown to be associated with schizophrenia.
We also conducted an overlap analysis between MGS and SSCCS datasets based on a single
run of piMASS without the permutation test. The results of the piMASS analysis of the
SSCCS dataset based on sum of PIPs for each region are presented in Figure 2.3. Figure 2.4
shows the Manhattan plot based on individual PIPs using − log10 (1− PIP ) as the y-axis.
The overlap analysis suggests that 46.3% of the pairs were in LD with each other in the
100, 000 bp overlap among top 1% of the SNPs of the top 5% of the regions. rs7746199
chr6:27261324 belongs to extended MHC region and has been previously implicated in as-
sociation with schizophrenia [Shi et al., 2009]. rs7746199 as well as rs2747421, rs2535238,
rs375984, rs2747421, rs2535238, rs375984 SNPs are in the consensus set and are in LD with














Figure 2.3: piMASS genome-wide region-based performance of the SSCCS dataset. The sum
of posterior inclusion probabilities (PIPs) for each of the 1244 overlapping regions spanning
22 chromosomes of the SSCCS dataset
Figure 2.4: Manhattan plot of 1-PIP for the SSCCS dataset
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2.5 Discussion
Guan and Stephens developed a BVS regression model for large-scale datasets primarily
focusing on analysis of quantitative traits [Guan and Stephens, 2011]. In this study, we used
the BVS regression model to conduct a case-control GWAS of schizophrenia with binary
phenotype for datasets with moderate sample sizes (cases/controls for MGS and SSCCS
datasets are 2, 681/2, 653 and 2, 895/3, 836, respectively). We have demonstrated that the
BVS methods can discover association signals that otherwise would need a much larger
sample size to discover.
Application of BVS to the MGS European ancestry case-control sample produced 17 re-
gions having Pdisc < 8 × 10−4 based on 100,000 permutations. Among them, 12 regions
were validated using the SSCCS dataset with Pvali ≤ 0.002 based on 1, 000 permuta-
tions. The region with the smallest p-value, which belongs to chromosome 15 reached
genome-wide significance. SNPs with the highest PIP from this region are mapping to
gene NTRK3 that encodes a member of the NTRK family and has been reported to be
associated with bipolar and other psychiatric disorders. Five SNPs among the twelve vali-
dated regions are mapped to genes that are known to be associated with schizophrenia and
other mental disorders, such as bipolar disorder, eating disorder, adolescent idiopathic sco-
liosis, psychosis, recurrent major depressive disorder [Wang et al., 2010], [Liu et al., 2016],
[Kanazawa et al., 2013], [Levine et al., 2012], [Liu et al., 2018], [Hall et al., 2018]. A cluster
of six SNPs on chromosome 19 are found to be in high LD with rs2905426, which is mapped
to the regulatory region of GATAD2A and MAU2, genes that are known to be associated
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with schizophrenia and bipolar disorder [Ripke et al., 2014].
Our BVS analysis of the MGS European ancestry case-control dataset identified one region
that reached genome-wide significance, while the original GWAS of the MGS case-control
dataset that used single-SNP approach did not find any significant signal [Shi et al., 2009].
This result indicates that piMASS method has the potential to uncover more associations
even in moderate sample size setting, as compared with the single-SNP approach. Our results
suggest that BVS methods, such as piMASS, can be used to reanalyze published datasets to
discover new risk variants for many diseases without new sample collection, ascertainment,
and genotyping.
Our analysis produced a single region that achieved genome-wide significance that has not
been reported in large-scale schizophrenia GWAS. The region is on chromosome 15 containing
SNPs between 83, 907, 801 and 86, 887, 657. Among SNPs with top 1% highest PIP in this
region is rs16940789 in the genes LINC00052 and NTRK3.
While we were able to demonstrate the potential superiority of piMASS over standard GWAS,
there are a few ways it could be further improved. First, performing genotype imputation for
both the discovery and validation datasets could provide more precise comparison between
the two datasets. Imputation enables direct comparison between datasets, which could be
beneficial to the understanding of the piMASS performance. Second, given that population
stratification and cryptic relatedness are among the confounding factors in genetic associa-
tion studies [Astle et al., 2009], [Price et al., 2010], a strategy that accounts for population
structure could improve the accuracy of association discovery and extend the application to
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datasets with less homogeneous population structure. Third, comparison of piMASS with
other methods beyond single-SNP approach can help placing it in a hierarchy of other GWAS
tools for real data. Another potential direction of further research is the extension of the
model to handle categorical response data, thus allowing to analyze phenotypes with poly-
chotomous scale such as addiction and other diseases. The classical approach to multinomial
response data is to fit a categorical response regression using maximum likelihood and make
inference about the model based on the associated asymptotic theory. It has been pointed
out that the inference based on the classical approach is questionable for small sample sizes
and Bayesian methods provided an attractive alternative [Albert and Chib, 1993]. Having
reached the conclusion that it is possible to uncover more associations using single dataset
with moderate sample size, it now makes sense to move on to apply piMASS to larger, more
heterogeneous datasets, imputed datasets and ultimately perform meta-analysis of the re-
sults of the BVS analysis of multiple datasets.
2.6 Data availability
The molecular genetics of schizophrenia (MGS) data and batches 5 and 6 of the Swedish
Schizophrenia CaseControl Study (SSCCS) data that support the findings of this study
are available in the NIMH Genetic Repository and Resource (https://www.nimhgenetics.
org/) upon approval of NIMH.
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2.7 Code availability
The code used to generate the output has been uploaded to GitHub public repository (https:




BAYESIAN VARIABLE SELECTION METHOD
WITH POPULATION STRATIFICATION
CORRECTION FOR GWAS WITH CONTINUOUS
PHENOTYPE
3.1 Background
When performing GWAS, the unknown covariance structure stemming from ignored origin of
individuals from multiple populations (population stratification) or their relatedness can lead
to false association signals, not related to the association of tested genetic marker and phe-
notype. Current pooled large scale genetic data sets can contain distantly related subjects.
Such genetic relatedness prevents standard association studies from correctly identifying the
causal variants and leads to many false positive associations [Martin and Eskin, 2017]. Some
studies suggest that modest amounts of stratification can exist even in well-designed studies
[Freedman et al., 2004]. Therefore, controlling for those confounding factors is important for
precise identification of genetic associations.
There is evidence that in multi locus BVS models, genetic relationship between individuals
can be captured by genetic markers themselves [Kärkkäinen and Sillanpää, 2012]. Other
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studies suggest that inclusion of additional covariates should significantly improve the power
of BVS models [Banerjee et al., 2018]. It is possible that some applications of Bayesian
association models can benefit from incorporating population stratification covariates
[Iwata et al., 2009]. In this chapter we explore such solution for BVS method piMASS for
GWAS with continuous phenotype.
Various methods have been developed to correct for population stratification. Those methods
could be divided into two broad categories. In the first category, there are methods such
as genomic control, which assume that unobserved genealogy is creating dependence among
individuals, thus inflating the regular test statistic and one can directly estimate dependence
structure and use it to correct the test statistic [Devlin and Roeder, 1999]. In the second
category, population membership or proportion of ancestry from different populations can
be thought of as unmeasured covariates [Wu et al., 2011]. One such method is the method of
structured associations, which uses a set of unlinked genetic markers to estimate the ancestry
of sampled individuals to use in the association test [Pritchard et al., 2000]. Another such
method is the method of principal components, which uses top eigenvectors of the sample
covariance matrix as covariates in a regression setting [Price et al., 2006]. In this chapter,
we want to include the non-genetic covariates accounting for population stratification in the
BVS multiple regression model. This makes the suggested approach similar to the methods
from the second category.
In section 2 we propose a BVS model with additional covariates that can control for popu-
lation stratification for continuous phenotypes. In section 3 we provide the description and
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results of simulation studies evaluating the performance of the proposed model. In section
4 we discuss the results and point out directions for further research.
3.2 Methods
3.2.1 Priors for non-genetic covariates
Following the approaches that include population stratification covariates in the regression
model, we want to incorporate the confounding variables into piMASS to account for their
effects.
Consider a multiple linear regression model for subject i:
yi = µ+ α1xi1 + ...+ αqxiq + β1gi1 + ...+ βpgip + εi, (3.1)
where yi is the phenotype of subject i, µ is an intercept, xi1, ... , xiq are q non-genetic co-
variates that can be used to account for population stratification and α1, ... , αq are their
corresponding regression coefficients, gi1, ... , gip are p genetic variants measured at ith indi-
vidual with their corresponding regression coefficients β1, ... , βp and εi is an error term. We
assume that εis are independent and identically distributed with εi ∼ N(0, τ−1).
The relationship between the phenotype vector y, genotype matrix G and covariate matrix
X can be expressed as:
f(y|α,β, τ) = Nn(µ+Xα+Gβ, τ−1In), (3.2)
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where y is an n-vector of phenotypes for n individuals, X is an n× q matrix of non-genetic
covariates, α is a q-vector of the corresponding regression coefficients, G = (g1, ... , gp) is
an n× p matrix of p genetic variants. Here gj = (g1j, ... , gnj)′ is a column vector containing
the observed values of jth genetic variant or SNP at the n individuals. Effects of the genetic
variants are of primary interest and are represented by a p-vector β.
Following the framework laid out in Chapter 1, we use a vector of binary indicators de-
fined in (1.3) to represent possible models describing the relationship between response and
covariates:






where Gγ denotes the matrix G restricted to those columns j for which γj = 1 and βγ is a
corresponding vector of regression coefficients. Here, selection is performed only for genetic
covariates and all members of X are always included in the model.
The priors on the model parameters τ, µ,γ,β and their corresponding hyperparameters are
the same as in piMASS and are given by equations (5.4)-(5.8). Next, we specify the prior for
the set of parameters α. When choosing a prior for α we consider its two main properties: it
should reflect our prior knowledge and be reasonable in terms of computational complexity.
In cases when we do not have enough information about parameters, which in our case is
true for α, we can instead construct a prior that is minimally informative to reflect the state
of our prior knowledge [Hoff, 2009]. Therefore, for the set of parameters α we propose a unit
information prior [Kass and Raftery, 1995].
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The unit information prior is derived in the following way. In (3.3), the precision of α




. Since it can be viewed as information contained in n


















where q is the number of non-genetic covariates included in the model. One advantage of
such prior is that the estimation is invariant to the change in the scale of the covariates
[Hoff, 2009]. The proposed prior distribution cannot be considered a real prior distribution,
as it requires knowledge of y to be constructed. Nevertheless, the amount of information
used is small and can be thought of as the prior distribution of a person with unbiased but
weak prior information [Hoff, 2009].
3.2.2 MCMC scheme for additional covariates
Our MCMC setting preserves most of the parameter updates of piMASS. This allows us to
perform the genetic covariate selection while accounting for the effects of additional covari-
ates, such as the ones accounting for population stratification.
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The priors for parameters as well as hyperparameters are listed below in detail:
τ ∼ Γ(λ/2, k/2),
µ|τ ∼ N(0, σ2µ/τ),
γj ∼ Bernoulli(π),
βγ |τ,γ ∼ Ndγ
(
0 , (σ2a/τ) Idγ
)
, (3.5)
β−γ |γ ∼ δ0,














where λ, k, σµ,M, p, n are given constants, U(x|a, b) = 1b−a is the continuous uniform density
function, Γ(x|a, b) = ba
Γ(a)





is the probability density function of a Normal distribution, Bernoulli(x|π) = πx(1−π)1−x is




is the probability density of a multivariate normal distribution.
There are several practical solutions that were implemented to facilitate computational sim-
plicity. First, by centering the response variable and the covariates (genetic and non-genetic)
to have mean 0, we set µ = 0 in the model. Additionally, the maximum number of SNPs
considered for association with the phenotype, M , is set to 300 to limit the computational
burden.
We initialize the model parameters by sampling values from their respective prior distribu-
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tions or setting them to previously specified values. We use φ(0) to denote the set of initial
values of the model parameters:
φ(0) = {h(0), π(0),γ(0), τ (0),µ(0),α(0),β(0)}. (3.6)
Under the conditions described in (3.5) and denoting pr(h, π,γ,α,β, τ) as a joint prior on
model parameters, the posterior distribution is proportional to the following expression:
p(h, π,γ,α,β, τ |y) ∝ L(y|h, π,γ,α,β, τ)× pr(h, π,γ,α,β, τ)
= L(y|h, π,γ,α,β, τ)× p(h)× p(γ|π)× p(π)


















βγ | 0, τ−1Idγ
)
× Γ(τ |λ, k).
(3.7)
In Bayesian inference, we first require the joint posterior distribution of all unknowns, and
then we integrate this distribution over the unknowns that are not of immediate interest to
obtain the desired marginal distribution of the parameters of interest [Gelman et al., 2013].
Here, explicitly computing the normalizing constant for our model and providing the full
posterior distribution in closed form is problematic due to the high dimensionality of the
parameter space. Therefore, we introduce MCMC sampling scheme needed to perform the
estimation of the proposed model.
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Let
Z = y −Xα. (3.8)
Then Z contains the variation in y left after subtracting the current estimates of the effects
α of the confounding variables X. Therefore, the distribution of Z is
Z|γ,β,G, τ ∼ Nn(Gγβγ , τ−1In), (3.9)
which is the distribution of the phenotype assumed in piMASS. Here, the conditional distri-
bution of Z follows the model originally proposed in [Guan and Stephens, 2011]. Since the
effects of non-genetic covariates have been accounted for, we can apply the MCMC scheme
proposed in piMASS to Z. Next, we examine the posterior conditional distribution of the
parameters (3.7) to determine the detailed updating strategies.
Parameters h, π,γ
In (3.7) we pull out the densities for h, π,γ to obtaint samples from their joint posterior
distribution on the product space (0, 1)× (0, 1)× {0, 1}p, which is given by:
p(h, π,γ|Z) ∝ p(h)× p(γ|π)× p(π)× p(Z|h, π,γ)






where p(Z|h,γ) can be computed by integrating out β and τ analytically
[Guan and Stephens, 2011]. Since the full conditional distributions for h, π,γ are not avail-
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able in closed form, we use Metropolis-Hastings algorithm. Metropolis-Hastings algorithm
requires neither proposal distribution to be symmetric nor posterior conditional distribution
to be in a closed form. Below we describe the joint Metropolis-Hastings update for h, π,γ
in detail.
First, the proposal distributions for h, π,γ are the following.
Propose γ∗ using piMASS rank-based proposal [Guan and Stephens, 2011]. The proposal
adds, removes or switches a single γi component. The proposal to remove as well as switch
(add and remove) a covariate is uniform. The proposal to add a covariate is a mixture of
uniform and rank-based selection. Rank-based selection chooses among the covariates with





(Z ′Z −Z ′XγΩX ′γZ





j γj, γi is a vector with all its components equal to zero, except the i-th
component, Ω is defined in (1.34) and σa is defined in (1.30).
Here, we choose the proposal to add a covariate to be 30% rank-based and 70% uniform (vs.
70% rank-based and 30% uniform in the original piMASS). Since we expect confounding
variables to have an effect that is not captured by genetic covariates, we prefer to rely less
on the marginal associations and allow more random exploration of the covariates when
adding a covariate. Such setting is desirable in a situation with confounding variables. More
details on the proposal distribution for γ can be found in [Guan and Stephens, 2011].





|γ∗|, p− |γ∗|+ 1
)
. (3.12)
Proposal distribution for h is a random walk
h∗ = h(s) + U(−0.1, 0.1), (3.13)
where h(s) is the current value of h at s-th iteration.
Let θ = (h, π,γ), then θ(s) denotes the current value of θ at the s the iteration and θ∗
denotes the proposed value. We will update θ(s) using Metropolis-Hastings algorithm.





















where p(θ|Z) is the target probability distribution given in (3.10) and Js is a joint pro-
posal distribution for θ(s). Sample r from U(0, 1) and set θ(s+1) = θ∗ if r < rMH , otherwise




Since posterior conditional distributions are known explicitly, we use Gibbs sampling to
sample β and τ . For each value of h,γ sampled from their posterior, we obtain samples
from the posterior distribution of β and τ by sampling from their conditional distributions
given Z,γ, h, which are available analytically.
Parameter τ has gamma posterior conditional distribution given Z,γ, h:
τ |Z, h,γ ∼ Γ(n/2, 2/(Z ′Z −Z ′XγΩX ′γZ)). (3.15)
Parameters βγ have multivariate Gaussian posterior conditional distribution given Z, h,γ, τ :
βγ |Z, h,γ, τ ∼ N(ΩX ′γZ, (1/τ)Ω). (3.16)
Parameters β−γ are sampled from
β−γ |Z, h,γ, τ ∼ δ0, (3.17)
where δ0 denotes a point mass on 0.
Parameters α
Now we introduce the variable Q, which contains the variation left after accounting for
current estimated effects of genetic covariates:
Q = y −Gγβγ . (3.18)
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HereQ contains the variation due to non-genetic covariates in the phenotype. Its distribution
is
Q ∼ Nn(Xα, τ−1In), (3.19)
and its likelihood is




[Q′Q− 2α′X ′Q+α′X ′Xα]
)
. (3.20)
Using Q, we sample the coefficients of non-genetic covariates α from their posterior distri-
bution. Under the prior (3.4) and likelihood (3.20) the posterior conditional distribution of
α given y,X, τ is multivariate normal
















where the value of τ is obtained from (3.15).
3.3 Simulations
We perform simulation studies to investigate how well our method identifies associations with
causal variants and compare the results to the model piMASS. We conducted simulations
on two types of genetic data: computer simulated and real genotypes, and we use Receiver
Operating Characteristic (ROC) curves to assess the performance of the proposed method.
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3.3.1 Simulated data
To test the model described above we simulate data consisting of genetic variants, non-genetic
covariates and phenotype. Below is the description of the simulation of each necessary part.
1. Genetic variants. We conducted simulation studies using two types of genetic variants:
independent genetic variants simulated using package COSI2 [Shlyakhter et al., 2014] and a
subset of real genotype data from the MGS data set described in [Shi et al., 2009].
Using package COSI2 we simulated 1000 uncorrelated SNPs. The package produces simu-
lated data that closely resemble empirical data in allele frequency, linkage disequilibrium,
and population differentiation [Schaffner et al., 2005]. We chose to simulate SNPs of Euro-
pean ancestry. The simulated SNPs comprise matrix G with dimensions n× p with n = 500
subjects and p = 1, 000 SNPs. For real genotypes, we select a subset of 1, 000 SNPs and 500
subjects from a larger MGS data set containing 5, 334 subjects and 638, 937 SNPs. Both
data sets are of the same size in terms of number of subjects and SNPs.
2. Non-genetic covariates. Our goal is to consider the situation where there is a correlation
between genetic variants and additional covariates. First, we randomly selected 5 genetic
variants gk, k = 1, ... , 5 from 1, 000 SNPs. Each new covariate is generated from gk in the
following way:
Xk = gk + εk, (3.22)








, where d is the smallest difference between
adjacent unique gij values [Chambers, 2018]. Next, we standardize Xk to set µ = 0 in (3.2).
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Non-genetic covariates comprise matrix X of dimensions n × q, q = 5. Each covariate Xi
is correlated with the corresponding genetic variant. Average correlation among 5 pairs of
genetic and derived non-genetic covariate is 0.75. Situation, where non-genetic covariates,
such as Principal Components (PC), are correlated with certain SNPs is desirable, since
PC-correlated SNPs can be used to successfully predict structure and ancestry proportions
[Paschou et al., 2007].







xikαk + εi, (3.23)
where C is a set of 3 causal variants randomly selected from the available 1, 000 genetic







and error term εi ∼ N(0, 1).
We generate two complete datasets. First dataset consists of independent genetic variants,
non-genetic covariates derived from it and 100 phenotypes generated using the combination
of genetic and non-genetic data. Second dataset consists of real genetic variants, non-genetic
covariates and 100 phenotypes generated using (3.23).
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3.3.2 Simulation results for independent COSI genotype
We applied both piMASS and the proposed method to the simulated data set with inde-
pendent genotypes with 50, 000 MCMC iterations. To lessen auto-correlation among the
sampled values, we sampled values every 10 iteration, thinning the MCMC output to a total
of 5, 000 samples. We did not detect any lack of convergence by looking at trace plots and
Gelman-Rubin (GR) convergence diagnostics. Both methods produce the posterior inclusion
probability (PIP) for each SNP. The PIP is given by:
PIPi =
number of iterations with i-th SNP included in the model
total number of iterations
, i = 1, ... , n. (3.24)
Overall, larger PIP signals stronger observed association with the phenotype under the pro-
posed model. We use PIPs and ROC curves to evaluate the performance of the two methods.
The proposed model can be viewed as a classification model with continuous output (PIP),
which estimates class membership probability (associated or not associated with phenotype)
[Fawcett, 2006]. To produce an ROC curve, different thresholds are applied to predict class
membership. For any given threshold, we consider all causal SNPs which PIPs exceed the
threshold to be true positives and all other SNPs with PIPs exceeding the threshold to be
false positives. Each point on the graph represents a threshold with the x-coordinate being
a false positive rate (FPR) or 1-specificity, which can be calculated as:
FPR =
number of false positives
total number of negative cases in the data
(3.25)
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and the y-coordinate representing true positive rate (TPR) or sensitivity:
TPR =
number of true positives
total number of positive cases in the data
. (3.26)
Figure 3.1 contains ROC curves of the piMASS and proposed model.
Figure 3.1: ROC curves for independent genetic variants for the continuous phenotype
method
The new model’s ROC curve is in blue and it either coincides or is visibly above the ROC
curve generated by piMASS. To quantify this visual difference we use Area Under the Curve
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(AUC) measure. Larger AUC means better prediction ability of a classifier. By definition,
random classification of case and control subjects provides an AUC of 50% while perfect





Table 3.1: AUC measurements for independent genetic variants for the continuous phenotype
method.
The AUCs for the two methods are different, but pretty close together, so it is not clear
whether the difference in AUCs is random. To that end, we perform a significance test for
two ROC curves provided in R package pROC [Robin et al., 2011], DeLong’s test for two
correlated ROC curves [DeLong et al., 1988]. It reports p-valueAUC = 0.01477 under the
alternative hypothesis: true difference in AUC is not equal to 0. Since p-value is less than
standard significance threshold of 5%, we can conclude that it is unlikely that the observed
difference has occurred by chance.
Since AUC summarizes the entire ROC curve, a potential drawback of this metric comes from
including regions with low levels of specificity that frequently are not practically relevant
[Ma et al., 2013]. Thus, we turn our attention to Partial Area Under the Curve (PAUC)
measurement presented in Table 3.2, which measures AUC for chosen acceptable levels of
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FPR. Here we restrict the AUC measurement to FPR between 0 and 0.2. This measurement
is of more interest since the performance of the method is particularly important in the area




Table 3.2: PAUC measurements for independent genetic variants for the continuous pheno-
type method.
To see if the observed difference in PAUCs is random, we conduct the bootstrap test for two
correlated ROC curves. We obtain p-valuePAUC = 0.01249, yielding similar conclusions as
AUC metric that the observed difference is unlikely to have occurred by chance.
3.3.3 Simulation results for real genotypes
Now we present the simulation results that assess the performance of our method using
real genotype data. We ran both piMASS and proposed method for 50, 000 iterations. We
sampled parameter values every 10 iteration, thinning the MCMC output to a total of 5, 000
samples. We did not detect any lack of convergence while running standard diagnostic
procedures. We summarize the results below.
The ROC curve for the two methods are shown in Figure 3.2.
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Figure 3.2: ROC curves for real genetic variants for the continuous phenotype method
The new model’s ROC curve is in blue and is visibly above the black curve for the benchmark
model piMASS, however, it is not clear by how much. To quantify this visual difference, we




Table 3.3: AUC measurements for real genetic variants for the continuous phenotype
method.
To test the significance of the observed difference in AUCs, we perform a DeLong’s signif-
icance test for two ROC curves provided in pROC package R, which yields p-valueAUC =
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0.002198. This leads to the conclusion that the observed difference in AUCs is unlikely to
have occurred by chance.
To focus on the practically relevant FPR between 0 and 0.2, we calculate PAUCs for each




Table 3.4: PAUC measurements for real genetic variants for the continuous phenotype
method.
The bootstrap test for two correlated partial ROC curves with 2000 bootstrap iterations
yields p-valuePAUC = 0.002575. Given the obtained p-value, we can conclude that the
observed difference in the performance of two models is unlikely to have occurred by chance.
Both AUC and PAUC results for both simulated and real genetic variants show that the
difference between the proposed method and piMASS is unlikely to be random. We also
notice that the proposed method showed higher AUC for independent genetic variants 0.9417
vs 0.8887 for real genetic variants (Tables 3.1, 3.3). The same holds true for PAUC for
independents variants of 0.1454622 vs 0.1 for real genetic variants (Tables 3.2, 3.4). These
differences can be attributed to the fact that simulated genetic variants are independent and
uncorrelated, whereas the real genetic variants have natural correlation structure that might
be interfering with the new method’s ability to detect true associations.
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3.4 Conclusion
Herein, we have developed Bayesian multivariate linear regression method that measures
associations between genetic variants and phenotypes, while taking into account non-genetic
covariates that account for population stratification. We carried out the simulation studies
using both real and simulated genetic variants and compared the performance of the proposed
method to the piMASS.
Simulation results provided evidence that there is a nonrandom difference between the two
classifiers, with the new method performing better in terms of both AUC and PAUC for
data sets with both correlated and uncorrelated genetic variants. The observed difference in
the performance of the proposed method between the two data sets hints at a possible role
of the correlation structure of the genetic variants. Thus, taking into account the correlation
structure of the genetic variants is one possible direction for further research.
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CHAPTER 4
BAYESIAN VARIABLE SELECTION METHOD
WITH POPULATION STRATIFICATION
CORRECTION FOR GWAS WITH BINARY
PHENOTYPE
4.1 Background
In GWAS, many complex disease phenotypes are often recorded as a binary variable. In
such studies, the goal is to compare the frequency distribution of genotypes between cases
and controls [Wu et al., 2011]. A difference in the allele frequency of an SNP between cases
and controls points at possible causal role of the SNP on the phenotype. However, presence
of undetected population stratification in large scale genetic studies can lead to both false
positives and failure to detect genuine associations [Marchini et al., 2004].
One way to account for population stratification is to use logistic mixed models (LMMs)
and include the variables accounting for spurious associations. Methods like PC-select
[Tucker et al., 2014] use LMM to account for population stratification in GWAS. EIGEN-
STRAT is another computationally efficient method that is widely used in single-SNP testing
setting [Price et al., 2006] . However, neither of the methods mentioned above is directly
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applicable to BVS.
Therefore, there is a need for a method that allows for population stratification correction
in Bayesian setting, since BVS is the method that can achieve the maximum power among
other GWAS multiple regression methods [Banerjee et al., 2018]. One way to account for
additional covariates in Bayesian setting is by modelling binary response using the idea of
data augmentation [Albert and Chib, 1993]. A population stratification correction method
that can work with BVS in case-control settings has the potential to yield results superior
to the existing methods. We introduce such a method in the sections below.
The rest of the Chapter is organized as follows. Section 2 provides the theoretical framework
for including additional covariates in piMASS when the trait of interest is binary. Section
3 contains simulation studies using an independent set of genotype data generated using
COSI2 and a subset of the MGS genotype data. The studies compare the performance of
the proposed method to piMASS. Section 4 contains real data analysis using the Alzheimer’s
Disease Neuroimaging Initiative 1 (ADNI1) dataset.
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4.2 Methods
4.2.1 Data augmentation approach
A standard data augmentation approach [Albert and Chib, 1993] is to create n latent vari-
ables Z1, ... , Zn, where Zi are independent
Zi ∼ N(µ+ α1xi1 + ...+ αqxiq + β1gi1 + ...+ βpgip, 1), (4.1)
where τ is set to a fixed value of 1 to avoid the improper posterior on τ and Z
[Albert and Chib, 1993]. Then Z = (Z1, ... , Zn) is assumed to follow a linear regression
model:
Z | µ, τ,β, X,G ∼ Nn(µ+Xα+Gγβγ , In), (4.2)
which is the model for continuous outcome introduced in Chapter 3.
The relationship to the observed outcomes yi is defined in the following way:
yi =
{
0, if Zi < 0,
1, if Zi ≥ 0.
Then, the observed variables yi are independent Bernoulli random variables
yi ∼ Bernoulli(pi), (4.3)
where pi is the probability of an outcome being a case.
Then the probit binary regression model is
pi = P (yi = 1 | β,α,γ,µ) = Φ(µ+ α1xi1 + ...+ αqxiq + β1gi1 + ...+ βpgip), (4.4)
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where Φ is the Gaussian cumulative distribution function connecting the probabilities pi to
the explanatory variables.
Zi are unknown, however, given the observed yi, Zi follows a truncated normal distribution
[Albert and Chib, 1993]
Zi|y,β,α,γ ∼ N(µ+Xα+Gγβγ , 1) truncated at the left by 0 if yi = 1 (4.5)
Zi|y,β,α,γ ∼ N(µ+Xα+Gγβγ , 1) truncated at the right by 0 if yi = 0 (4.6)
This approach connects the probit binary regression model on the yi with a normal linear
regression model on the latent data Zi. Posterior inference requires one additional update
of the Z variables compared to the quantitative trait.
4.2.2 MCMC scheme for binary phenotypes
MCMC setting for binary phenotype preserves most of the parameter updates described in
Chapter 3.
The approach described above allows usage of the same priors as for continuous data, only
these priors now relate to the unobserved latent continuous variables and not to the observed
binary outcomes.
A few practical constraints were suggested by Guan & Stephens [Guan and Stephens, 2011]
to ensure identifiability and improve mixing. First, an identifiability constraint was im-
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posed on Z to have empirical variance 1. Second, we center all variables and set µ = 0.
Third, to improve mixing, we make an assumption that marginal distribution of Z is nor-
mal [Guan and Stephens, 2011]. In particular Zi, ..., Zn|y are restricted to take fixed set of
values, which are n equally spaced quantiles of standard normal distribution with the val-
ues corresponding to n0 individuals with yi = 0 being constrained to the first n0 of those
quantiles. This is a reasonable assumption if we there are no large values of β.
Local Metropolis-Hastings proposals for Z involve randomly picking a pair of individu-
als (m,n) with the same binary phenotype and propose to swap values Zm and Zn. The
Metropolis-Hastings ratio is calculated using (3.14) while using Z as an outcome variable
and the decision to accept or reject the proposed Z as well as other proposed parameters is
based on it.
4.3 Simulations
We conducted simulation studies to see how well our method identifies associations with
causal variants when the phenotype is binary and compare the results to piMASS. We per-
formed simulations on two types of genetic data: computer simulated and real genotypes,
and we use ROC curves to assess the performance of the methods.
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4.3.1 Simulated data
To test the model, we generate 3 necessary components: genetic variants, non-genetic co-
variates and the phenotype.
1. Genetic variants. We conducted simulation using two types of genetic variants: inde-
pendent genetic variants simulated using the COSI2 package [Shlyakhter et al., 2014], and
a subset of real genotype data from the MGS data set described in [Shi et al., 2009]. The
independent genetic variants we used are the same as in Chapter 3 and comprise genotype
matrix G with dimensions n × p with n = 500 subjects and p = 1, 000 SNPs. The real
genetic variants are a subset of 1, 000 subjects and 9, 306 SNPs of chromosome 21 from a
larger MGS dataset containing 5, 334 subjects and 638, 937 SNPs.
2. Non-genetic covariates. As in Chapter 3, our goal is to consider the situation where
there is a correlation between genetic variants and additional covariates. First, we randomly
selected 5 genetic variants gk, k = 1, ... , 5 from 9, 306 SNPs. Each new covariate is generated
from gk in the following way:
Xk = gk + εk, (4.7)








, where d is the smallest difference
between adjacent unique gij values [Chambers, 2018]. Next, we standardizeXk. Non-genetic
covariates comprise matrix X of dimensions n × q, q = 5. Each covariate Xi is correlated
with the corresponding genetic variant. Average correlation among 5 pairs of genetic and
derived non-genetic covariate is 0.79. Top eigenvectors or principal components (PCs) of a
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genetic relatedness matrix are often used as additional covariates in population stratification
correction [Price et al., 2006]. Our simulated high correlation between SNPs and additional
covariates is desirable since in some situations, SNPs, correlated with the PCs of the genetic
relatedness matrix, can be used to successfully account for population structure and ancestry
proportions [Paschou et al., 2007].







xikαk + εi, (4.8)
where for COSI genotypes C is a set of 3 variants randomly selected from the available 1, 000
genetic variants, and for real genotypes C is a set of 10 variants randomly selected from 9, 306
genetic variants. The effects of genetic variants are βj ∼ N(0, 1), the effects of non-genetic






, and the error term εi ∼ N(0, 1). Next, we convert
these n quantitative phenotypes to n binary phenotypes by mapping the smallest n/2 values
to y = 0 and the rest to y = 1. We generate two complete datasets. Both datasets consists
of genetic variants, non-genetic covariates and 100 phenotypes generated using (4.8).
4.3.2 Simulation results for independent COSI genotypes
We applied both piMASS and the proposed method to the simulated data set with indepen-
dent genotypes. For the results provided below, we ran 50, 000 MCMC iterations.
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To reduce auto-correlation among the sampled values, we sampled parameter values every 10
iterations, leaving a total of 5, 000 samples. We did not detect lack of convergence by looking
at trace plots and Gelman-Rubin (GR) convergence diagnostics. Both methods produced
the PIP for each SNP. We use ROC curves to evaluate the performance of the two methods.
Figure 4.1 contains ROC curves of the piMASS and proposed model.
Figure 4.1: ROC curves for independent genetic variants for the binary phenotype method
The new model’s ROC curve is in blue and it is visibly above the ROC curve generated by
piMASS. To quantify this visual difference we use AUC measure. AUCs for the two methods





Table 4.1: AUC measurements for independent genetic variants for the binary phenotype
method.
The AUCs for the two methods are different, however we still conduct the DeLong’s test
for two correlated ROC curves to see if the difference in AUCs is random. The test reports
p-valueAUC = 0.09434 under the alternative hypothesis: true difference in AUC is not equal
to 0. Although the p-value is larger than standard significance threshold of 5%, it is still
unlikely that the observed difference has occurred by chance. It is possible that two methods
have similar power to detect associations on the provided dataset.
To investigate the practically relevant areas of specificity, we provide PAUC measurement
presented in Table 4.2. PAUC measures AUC for chosen acceptable levels of FPR. Here we




Table 4.2: PAUC measurements for independent genetic variants for the binary phenotype
method.
To see if the observed difference in PAUCs is random, we conduct a bootstrap test for two
correlated ROC curves. We obtain p-valuePAUC = 0.2718, which means it is likely that the
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performance of the two methods is similar in the selected range of specificity for a given
dataset.
4.3.3 Simulation results for real genotypes
Now we present the simulation results that assess the performance of our method for binary
phenotypes using real genotype data of the size n×p, n = 1, 000 individuals, p = 9, 306 SNPs,
which is a subset of the MGS dataset described in [Shi et al., 2009] and is availablein the
NIMH Genetic Repository and Resource (https://www.nimhgenetics.org/) upon approval
of NIMH.
We ran both piMASS and proposed method for 80, 000 iterations. To reduce auto-correlation
in the samples, we sampled parameter values every 10 iterations leaving a total of 8, 000
samples. We did not see any evidence for the lack of convergence while running standard
diagnostic procedures such as trace plots. We run both piMASS and the new method on the
real genotype data with 100 binary phenotypes each and summarized the results below.
Figure 4.2 contains ROC curves of the piMASS and proposed model for real genetic data
with binary phenotypes.
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Figure 4.2: ROC curves for real genetic variants for the binary phenotype method
The new model’s ROC curve is in blue and is visibly above the black curve for the bench-
mark model piMASS for most values of specificity, however, it is not clear by how much. To





Table 4.3: AUC measurements for real genetic variants for the binary phenotype method.
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To test the significance of the observed difference in AUCs, we perform a DeLong’s signif-
icance test for two ROC curves provided in R package pROC , which yields p-valueAUC =
0.07877. As with the previous datasets, this means that it is still unlikely that the observed
difference in AUCs have occurred by chance.
Next we focus on the practically relevant FPR between 0 and 0.2 and calculate PAUCs for




Table 4.4: PAUC measurements for real genetic variants for the binary phenotype method.
The bootstrap test for two correlated partial ROC curves with 2000 bootstrap iterations
yields p-valuePAUC = 0.07692. We can say that the observed difference in the performance
of two models is unlikely to have occurred by chance. It is possible that the models perform
similarly for a given dataset.
Since p-values do not measure the probability that the studied hypothesis is true
[Wasserstein and Lazar, 2016], we cannot conclude that the two methods are the same. In
this case the usefulness of the population stratification correction should be evaluated on a
case by case basis.
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4.4 Real data analysis
Alzheimer disease (AD) is characterized by progressive cognitive decline usually with short
term memory impairment and inevitably affecting all intellectual functions, leading to com-
plete dependence and premature death [Mayeux and Stern, 2012]. In 2019, 5.8 million Amer-
icans were living with Alzheimer’s dementia. Out of them 5.6 million age 65 or older, which
means 1 in 10 people age 65 or older has AD [Hebert et al., 2013]. Genetic factors play a
major role in determining a person’s risk to develop AD [Bertram and Tanzi, 2012]. AD her-
itability varies from 58-79% depending on age at onset; however, only a portion of the likely
substantial genetic contribution to this disease has been determined [Reitz et al., 2011].
We use dataset ADNI1 provided by Alzheimer’s Disease Neuroimaging Initiative (ADNI)
(http://adni.loni.usc.edu). ADNI seeks to develop biomarkers of the disease and ad-
vance the understanding of AD pathophysiology, improve diagnostic methods for early de-
tection of AD and improve clinical trial design. Additional goals are examining the rate of
progress for both mild cognitive impairment and Alzheimer’s disease, as well as building a
large repository of clinical and imaging data.
ADNI1 GWAS data set contains 620, 901 SNP and copy number variant (CNV) markers for
757 subjects (449 males, 308 females) genotyped using Illumina Human610-Quad BeadChip
platform with 3 types of Patient Diagnosis groups: Cognitively Normal (CN), Mild Cognitive
Impairment (MCI) and Alzheimer’s Disease.
Since we are interested in applying the new method to the data set with the binary pheno-
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types, we combined MCI and AD diagnosis patients to be cases in our analysis. We did it
for the following reasons. At present time, there is increasing recognition and understanding
of the MCI entity as a stage which is a frequent precursor and harbinger of subsequently
manifest AD [Reisberg and Gauthier, 2008]. MCI, as a stage in the evolution of subse-
quently manifest AD, has been estimated to have a duration of approximately seven years
[Reisberg, 1986]. Since the SNP data of the person diagnosed with MCI will not change in
seven years, we can use existing genetic data for MCI patients to enhance our AD analysis.
Neurotypical Controls serve as controls in our analysis.
Some methods apply the principal components analysis to genotype data to infer continuous
axes of variation, which reduce the data to a small number of dimensions, describing as much
variability as possible [Price et al., 2006]. Such axes of variation, also sometimes referred to
as principal components are often used as additional covariates in population stratifica-
tion correction [Price et al., 2006]. We selected top 5 eigenvectors of a genotype covari-
ance matrix to use as additional covariates. The PCs were obtained from ADNI1 genotype
data using package PLINK available at http://pngu.mgh.harvard.edu/purcell/plink/
[Purcell et al., 2007].
We ran the new method described above for 100, 000 MCMC iterations. We sampled every 10
iterations to reduce auto-correlation, which yielded 10, 000 samples. The standard diagnostic
procedures did not indicate any lack of convergence.
The Manhattan plot of the PIP of individual SNP using the ADNI1 dataset is shown in
Figure 4.3 using log10 (1− PIP) as the y-axis.
74
Figure 4.3: Manhattan plot of 1-PIP for ADNI1 data set for the binary phenotype method
Below we present a table containing top 30 SNPs that had the best association metric (PIP)
in our analysis.
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Chr rsID Position Rank PIP
5 rs7727368 133028407 1 0.21388
9 rs1186462 82876046 2 0.09573
6 rs9388462 126318495 3 0.08653
6 rs9345231 93201586 4 0.07474
6 rs3846829 24411174 5 0.07091
4 rs17793067 126391075 6 0.06987
4 rs6449272 16583116 7 0.06847
20 rs530008 862420 8 0.06263
7 rs4329193 141589735 9 0.05821
13 rs9576991 39806690 10 0.05651
9 rs2807302 81387555 11 0.05508
5 rs7724537 115331803 12 0.05369
9 rs7870046 77803715 13 0.05157
4 rs11132004 169215891 14 0.05101
2 rs873270 127575888 15 0.05089
12 rs1343660 80215275 16 0.04869
21 rs7282252 18188480 17 0.04834
5 rs2867327 133029144 18 0.04821
7 rs923823 53034446 19 0.04779
13 rs17079354 23269225 20 0.0451
5 rs10061143 80630102 21 0.04339
1 rs10802975 239880394 22 0.04168
13 rs9513661 99232340 23 0.04088
15 rs4777474 70005090 24 0.04055
4 rs7682461 98516722 25 0.03965
20 rs1739646 36470998 26 0.03937
5 rs828311 3619024 27 0.0384
2 rs2699150 36315894 28 0.03741
6 rs12203747 104803799 29 0.03736
8 rs2740898 3891496 30 0.03576
Table 4.5: Top 30 SNPs with largest PIP for the binary phenotype method
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We used GWAS catalog available at https://www.ebi.ac.uk/gwas to match SNPs with
high PIPs to the genes associated with Alzheimer’s disease. The top signal is rs7727368, an
intergenic SNP located at chr5:133000508 which has not been detected in previous studies.
However, rs7870046 (rank 13) is located at chr9:78613895 and is a part of the protein coding
gene PCSK5 which plays role in Alzheimer’s disease progression score [Scelsi et al., 2018].
Additionally, rs2740898 (rank 30) is located at chr8:3904088 and is a part of protein coding
gene CSMD1 which influences Alzheimer’s disease cognitive decline [Sherva et al., 2014] and
Alzheimer’s disease with visuospatial domain impairment [Mukherjee et al., 2018]. Next,
rs3846829 (rank 5) is located at chr6:24303195 is a part of the DCDC2 gene influencing
information processing speed [Luciano et al., 2011] and intelligence [Davies et al., 2018].
rs2807302 (rank 11) is located at chr9:82197735 is a part of the TLE4 gene and is associated
with bipolar disorder [Jiang and Zhang, 2011] and mathematical ability [Lee et al., 2003].
rs1343660 (rank 16) is located at chr12:81691144 and is a part of the protein coding gene
PPFIA2 which is implicated in self reported educational attainment [Rietveld et al., 2014]
and schizophrenia [Levinson et al., 2012]. rs17079354 (rank 20) is located at chr13:24371225
and is a part of the protein coding gene MIPEP which is implicated in smoking behav-
ior [Park et al., 2015]. rs10802975 (rank 22) is located at chr1:241813771 is a part of the
OPN3 gene influencing response to antidepressants [Fabbri et al., 2019] and gut microbiome
measurement [Hughes et al., 2020]. rs9513661 (rank 23) is located at chr13:100434339 and
is a part of the protein coding gene CLYBL which is implicated in smoking behavior
[Wootton et al., 2019]. rs7682461 (rank 25) is located at chr4:98297699 is a part of pro-
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tein coding gene STPG2 which is implicated in intelligence [Savage et al., 2018] and alcohol
consumption measurement [Brazel et al., 2019].
There are several reasons why we did not find the signals discovered in large Alzheimer’s
GWAS [Jansen et al., 2019], [Kunkle et al., 2019], [Waring and Rosenberg, 2008],
[Bertram and Tanzi, 2009] in the current analysis. First, the signal tends to be spread among
correlated SNPs and any single SNP may not get a large value of PIP to stand out. Next,
since here we are using unimputed data, we can only find associations with the markers that
are present in the ADNI1 data set. Finally, in this particular application, we used relatively
small number of iterations compared to the number of genetic variants in the data set. This
means that there was less opportunity to explore the large amount of SNPs. Due to all the
factors mentioned above, the results received are expected. For a more thorough analysis,
additional efforts should be applied. However, we were able to demonstrate the ease of use
and applicability of the proposed method.
4.5 Conclusion
In this chapter we provided a BVS method for GWAS with binary phenotypes which provides
the measure of association between genotypes and phenotypes while taking into account
additional covariates that can account for population stratification.
We constructed the method using the data augmentation approach [Albert and Chib, 1993]
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and implemented a simplified version of the method by imposing additional identifiability
constraints.
We carried out the simulation studies using both independent and real genetic variants.
We compared the performance of the proposed method to the piMASS using ROC curves.
Simulation results provided evidence that there is a difference between the two classifiers that
is unlikely to have ocurred by chance, however it is possible that performance of the two
methods for binary data with both correlated and uncorrelated genetic variants is similar.
Next we applied the proposed method to real genetic data with binary phenotypes from the
ADNI project whose goal is to develop biomarkers of the Alzheimer’s disease and advance
the understanding of its pathophysiology. The analysis showed some SNPs having strong
associations with the phenotype including several previously unknown markers. Overall, we
demonstrated the applicability of the method to the real data.
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CHAPTER 5
BAYESIAN VARIABLE SELECTION METHOD
FOR GWAS WITH ORDINAL PHENOTYPE
5.1 Background
Many GWAS phenotypes are often measured on continuous or binary scale. The tools
to treat binary and continuous data have been described in previous chapter. However,
some phenotypes naturally take ordered, discrete values. Examples include (a) subtypes
defined from multiple sources of clinical information and (b) derived phenotypes generated by
specific phenotyping algorithms for electronic health records (EHR) [German et al., 2020].
For many complex diseases such as substance use disorders or progression of Alzheimer’s
disease, phenotypes are often measured on ordinal scale. In that case, GWAS frameworks
developed for other data types are not directly applicable and require further adaptation.
Treating ordinal data as binary, continuous or multinomial leads to misleading inference,
loss of power and inconsistent results [German et al., 2020]. Therefore, the development of
methods that can utilize the information contained in ordinal phenotypes and still use the
advantages of a Bayesian approach is of potential benefit.
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Fitting ordinal regression using maximum likelihood is possible for single-SNP approaches,
but not applicable to BVS. There are several ways to connect the ordinal outcome to BVS.
One useful solution is the data augmentation framework developed for Bayesian modelling
with ordinal response [Albert and Chib, 1993]. There have been several methods proposed
in treating ordinal and categorical outcome for BVS [Sha et al., 2004], [Kwon et al., 2007].
However, those variable selection approaches were implemented for models not tailored to
GWAS. Here, we provide an approach that extends piMASS to work with ordinal phenotype
data. Below we provide the theoretical foundation for BVS with ordinal phenotype.
5.2 Extension to ordinal categorical phenotypes
Following our previous notation, we let X,y indicate the observed data. Here X =
(x1, ... ,xn)
′ is an n × p design matrix containing the set of p potential predictors, where
xi = (xi1, ... , xip)
′ is a column vector containing the observed covariates of the ith individ-
ual and y = (y1, y2, ... , yn)
′ is a response vector, where yi takes one of J ordered categories,
1, ... , J , where J > 2.
Each outcome yi is associated with a vector (pi1, pi2, ... , piJ), where pij = P (yi = j) is the
probability that individual i falls into jth category. Now define the cumulative probabilities
ηij = P (yi ≤ j) =
j∑
k=1
pik, i = 1, ..., n, j = 1, ..., J − 1 and ηiJ = 1. (5.1)
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Following data augmentation approach [Albert and Chib, 1993], we introduce n latent vari-
ables Z = (Z1, ..., Zn) into the problem. The Z is assumed to be an underlying continuous
variable that determines the value of y. The correspondence between Zi and yi is:
yi = j if sj−1 < Zi ≤ sj, i = 1, ..., n, j = 1, ..., J, (5.2)
where the boundaries s1, ..., sJ−1 are unknown, and −∞ = s0 < s1 < ... < sJ−1 < sJ =∞.
For the purposes of parameter identifiability, we set s1 = 0.
Now we use standard normal linear regression model to describe the relationship between
observed potential predictors X and latent variables Z. The probabilities ηij can be related
to the linear predictor in the following way:
ηij = Φ(sj − µ− x′iβ), i = 1, ... , n, j = 1, ... , J − 1, (5.3)
where Φ is the Gaussian continuous distribution function. This model is motivated by the as-
sumption that there exists a latent continuous random variable Zi distributed N(µ+x
′
iβ, 1),
where we set τ = 1 to avoid the improper posterior on τ,Z [Albert and Chib, 1993]. Now
the problem is reframed as a normal regression problem where the response is in the form
of the grouped data. In the model above, the vector of regression coefficients β and the bin
boundaries s2, ... , sJ−1 are unknown.
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Incorporating variable selection into the model
In a GWAS context, most predictors provide no information about the phenotype. To
identify relevant predictors, we introduce a binary inclusion/exclusion vector γ that induces
mixture prior on regression coefficients. Next, we specify the priors on model parameters:
τ ∼ Gamma(λ/2, k/2) (5.4)
µ|τ ∼ N(0, σ2µ/τ) (5.5)
γj ∼ Bernoulli(π) (5.6)
βγ |τ,γ ∼ Ndγ (0 , (σ2a/τ) Idγ ) (5.7)
β−γ |γ ∼ δ0, (5.8)
where δ0 is a point mass on 0 and λ, k, σµ, π and σa are hyperparameters. Hyperparameters
π, which reflects the model sparsity and σa, which reflects the typical size of a nonzero
regression coefficients are playing important roles in tailoring model to GWAS. The priors
on hyperparameters are also the same as in piMASS and are listed in equations (1.24) -
(1.30). Similar to [Guan and Stephens, 2011] we set µ = 0 and τ = 1. We also denote xiγ
as a vector whose entries correspond to the vector xi restricted to the values j for which
γj = 1 and βγ is the vector of corresponding regression coefficients.
For the remaining boundaries, we assign diffuse priors following [Kwon et al., 2007] that ex-
press no prior belief by setting the boundaries sj to be uniformly distributed on (sj−1, sj+1).
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5.2.1 MCMC algorithm
Next we provide the updating steps for the new parameters: the latent variables Z and the
boundary parameters s :
1. Update the vector of latent variables Z from its posterior distribution given β,γ, s,y,
which is a truncated normal density under the constraints defined in (5.2):
Zi | β,γ, s, y ∼ N(x′iγβγ , 1), (5.9)
truncated on the left by sj−1 and on the right by sj.
2. Update the boundary parameters sj from their posterior densities given Z,y,β, s−j where
s−j is the vector s without the j-th element.
This conditional distribution is uniform on the interval
sj|Z,y,β, s−j ∼ U(
[




as described in [Albert and Chib, 1993].
5.2.2 Implementation
To implement a MCMC setting for ordinal phenotypes, we extend the Guan and Stephens’
approach to handling binary phenotypes to ordinal categorical phenotypes, which preserves
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most of the parameter updates of piMASS. We implement the same practical constraints
that were suggested by Guan and Stephens [Guan and Stephens, 2011].
First, an identifiability constraint was imposed on Z to have empirical variance 1. Second,
we center all variables and set µ = 0. Third, to improve mixing, we make an assumption
that the marginal distribution of Z is normal [Guan and Stephens, 2011]. In particular,
Z1, ... , Zn | y are restricted to take a fixed set of values, which are set to be n equally
spaced quantiles of the standard normal distribution. The number of subjects in each of the
categories is n1, n2, ..., nJ , where n = n1 + n2 + ... + nJ . We assign the first n1 of these
quantiles to the n1 individuals with yi = 1, the next n2 of these quantiles to the n2 individuals
with yi = 2 and so on with the last nJ of these quantiles assigned to the nJ individuals with
yi = J . This way we create a Z vector with larger values of Z corresponding to larger value
of the observed phenotype. This is a reasonable assumption if there are no large values of
β. Let s2 = max
Zi
{yi = 2}, ... , sJ−1 = max
Zi
{yi = J − 1} be the initial values for s.
Local Metropolis-Hastings proposals for Z involve randomly picking a pair of individuals
(m,n) with the same ordinal phenotype (both 0, 1 or 2) and propose to swap their latent
response values Zm and Zn. The Metropolis-Hastings ratio is calculated using (3.14). The
decision to accept or reject the proposed Z and other proposed parameters is based on (3.14).
85
5.3 Real data analysis
We use dataset ADNI1 provided by Alzheimer’s Disease Neuroimaging Initiative (ADNI)
(http://adni.loni.usc.edu). ADNI1 GWAS data set contains 620, 901 SNP and CNV
markers for 757 subjects (449 males, 308 females) genotyped using Illumina Human610-Quad
BeadChip platform with 3 types of Patient Diagnosis groups: 214 Cognitively Normal, 363
Mild Cognitive Impairment, 180 Alzheimer’s Disease patients. Here we code the phenotype
as follows: 0-Cognitively Normal, 1-Mild Cognitive Impairment, 2-Alzheimer’s disease. We
use this phenotype with 3 categories in our analysis.
We applied the method proposed in this chapter to the data described above with 1, 000, 000
MCMC iterations. We sampled every 10 iterations, therefore reducing MCMC output to a
total of 100, 000 samples to reduce autocorrelation. The standard diagnostic procedures did
not indicate lack of convergence.
The results of the analysis are presented below. The Manhattan-like plot of the PIPs of
individual SNPs using the ADNI1 dataset is shown in Figure 5.1, with PIP on the y-axis.
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Figure 5.1: Plot of PIP for ADNI1 data set for the categorical phenotype method
To investigate the SNPs that visibly separate from the rest, below we present a table con-
taining top 30 SNPs with the best association metric (PIP).
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Chr rsID Position Rank PIP
2 rs4953672 42953942 1 0.07794
12 rs12822144 4176072 2 0.07572
19 rs2075650 50087459 3 0.0661
20 rs6116375 4399364 4 0.05996
8 rs2055195 26696942 5 0.04668
14 rs10133989 100949306 6 0.04305
12 rs2906109 1142624 7 0.02757
4 rs2306245 852156 8 0.02635
1 rs10924809 244929211 9 0.01981
3 rs11706690 398018 10 0.0189
22 rs17365991 40120125 11 0.01839
2 rs6731612 31199704 12 0.01711
20 rs530652 878560 13 0.01652
20 rs362584 10202475 14 0.01571
3 rs10804857 176728521 15 0.01402
10 rs6480572 53339650 16 0.01401
4 rs2279186 865887 17 0.01353
11 rs274492 11056714 18 0.01266
12 rs10506562 67295983 19 0.0118
15 rs734854 72068901 20 0.01159
6 rs9390855 96659997 21 0.01088
16 rs3751834 77573909 22 0.01087
6 rs86715 33588413 23 0.01062
12 rs4149577 6317783 24 0.00975
9 rs10973041 36713143 25 0.00974
14 rs17613673 98338710 26 0.00969
20 rs11906462 60569397 27 0.00945
7 rs9641952 132953992 28 0.00943
18 rs883218 45400797 29 0.00918
8 rs1382617 83474224 30 0.00908
Table 5.1: Top 30 SNPs with largest PIP for the categorical phenotype method
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First, we focus on the SNPs with the highest obtained PIP and investigate their role and
whether they have been implicated in previous studies. We used GWAS catalog available at
https://www.ebi.ac.uk/gwas to match SNPs with high PIPs to the genes associated with
Alzheimer’s disease as well as mental disorder related diseases.
The top signal is rs4953672, an intergenic SNP located at chr2:43100438 which has not
been detected in previous studies. The second best signal rs12822144 an SNP located at
chr12:4305811 within the intergenic region between RPL18P9 and CCND2 and has been
found to be associated with APOE ε-4 non-carriers of Alzheimer’s Disease [Jiang et al., 2015].
The third best signal rs2075650 is located at chr19:45395619 in TOMM40 gene. rs2075650
has confirmed highest association with the apolipoprotein E (APOE ) locus (P = 1.8×10−157)
[Harold et al., 2009]. rs2075650 was also found to be the top SNP associated with late-onset
Alzheimer’s dementia [Heinzen et al., 2010]. Other studies of late onset Alzheimer’s disease
also confirmed APOE ’s risk effect (P = 1× 10−36) [Naj et al., 2010]. Additionally, the locus
rs2075650 reached genome-wide significant evidence for association with AD at the APOE
(P = 1.04 × 10−295) [Seshadri et al., 2010]. The fact that our analysis with MCI patients
picked up this signal points at its potential role in the development of MCI.
Next, rs6116375 (rank 4), an intergenic SNP located at chr20:4451364 is known to be asso-
ciated with Alzheimer’s disease in whole-genome analyses of whole-brain data
[Huang et al., 2015]. rs2055195 (rank 5) is a part of the ADRA1A gene located at
chr8:26641025. The ADRA1A gene has been associated with grey matter volume measure-
ment [Alliey-Rodriguez et al., 2019]. rs2906109 (rank 7) is a part of ERC1 gene located at
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chr12:1272363 is in linkage disequilibrium (LD) with rs61913097 (R2 = 0.5981), which was
found to be associated with attention deficit hyperactivity disorder [Kweon et al., 2018].
rs2306245 (rank 8) is a part of the GAK gene and located at chr4:862156 is in LD with
rs11248051 (R2 = 0.2215), which plays a role in Parkinson’s disease [Hamza et al., 2010].
rs10924809 (rank 9) is located near SCCPDH at chr1:246862588. rs10924809 is in LD with
rs6426328 (R2 = 0.1048), which is known to be associated with apolipoprotein B measure-
ment [Richardson et al., 2020]. rs10924809 is also in LD with rs3007305 (R2 = 0.1863), which
is associated with schizophrenia, bipolar disorder, attempted suicide [Mullins et al., 2019].
Some SNPs that have not been mentioned before were not found to be in LD with known
markers, but map to genes associated with Alzheimer’s disease and other brain disorders. For
example, rs11706690 (rank 10) is a part of CHL1 gene and is located at chr3:423018. CHL1
gene is associated with Parkinsonism in frontotemporal lobe dementia [Pottier et al., 2018].
rs17365991 (rank 11) is located at chr22:41790179 and a part of the TEF gene. TEF gene
is associated with mood instability measurement [Nagel et al., 2018] and multiple sclerosis
[Beecham et al., 2013]. rs530652 (rank 13) is located at chr20:930560 and belongs to RSPO4
gene. RSPO4 is associated with logical memory (immediate recall) in Alzheimer’s disease
dementia [Chung et al., 2018]. rs10804857 (rank 15) is located at chr3:175245827 and is
mapped to NAALADL2 gene. NAALADL2 gene is associated with late-onset Alzheimer’s
disease [Mez et al., 2017].
Several markers were found to be in LD with markers highlighted in previous association
studies. There was a group of markers that were connected to the SNPs associated with
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various phenotypes reflecting the cognitive function. First, rs362584 (rank 14) is located
at chr20:10254475 in SNAP25 gene. rs36258 is in LD with rs362987 (R2 = 0.3957), which
is associated with self reported educational attainment [Rietveld et al., 2014]. Moreover,
rs9390855 (rank 21) is located at chr6:96553276 and is mapped to FUT9 gene. rs9390855
is in LD with rs7763181 (R2 = 0.1399), which is associated with self reported educational
attainment [Lee et al., 2018]. Additionally, rs6480572 (rank 16) is located at chr10:53669644
and is a part of PRKG1 gene. rs6480572 is in LD with rs10823860 (R2 = 1), which is as-
sociated with mathematical ability [Lee et al., 2018]. Also, rs9641952 (rank 28) is located
at chr7:133303452 and is mapped to gene EXOC4. rs9641952 is in LD with rs4728302
(R2 = 0.1312), which is associated with intelligence [Sniekers et al., 2017]. The variety of
highlighted SNPs points at links with various markers of person’s general cognitive perfor-
mance to MCI and AD.
Several associations were found to be connected to some other brain-related diseases like
multiple sclerosis and Parkinson’s disease. rs2279186 (rank 17) is located at chr4:875887 and
is mapped to GAK gene. rs2279186 is in LD with rs873786 (R2 = 0.1952), which is associated
with Parkinson’s disease [Nalls et al., 2019]. rs4149577 (rank 24) located at chr12:6447522 is
a part of TNFRSF1A and is in LD with rs1800693 (R2 = 0.5496), which is associated with
multiple sclerosis [Andlauer et al., 2016]. rs883218 (rank 29) is also in LD with rs28512338
(R2 = 0.1746), which is associated with multiple sclerosis [Consortium et al., 2019].
We also found a group of markers that are associated with various physical illnesses not
directly connected to the brain and its physiology. For example, rs6480572 (rank 16) is
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also in LD with rs10823893 (R2 = 0.2468), which is associated with body mass index
[Pulit et al., 2019]. rs734854 (rank 20) is located at chr15:74281848 and is mapped to
STOML1 gene. rs734854 is in LD with rs2507 (R2 = 0.2232), which is associated with
coronary artery disease [van der Harst and Verweij, 2018]. rs883218 (rank 29) is located
at chr18:47146799 is mapped to gene LIPG and is in LD with rs1105654 (R2 = 0.2359).
rs1105654 is associated with metabolic syndrome [Lind, 2019].
Since majority (63%) of the SNPs among the top 30 SNPs were mapped to genes with known
association with AD or other mental disorders, the top ranking SNP rs4953672 (rank 1) has
potential to be a novel marker associated with AD and the further investigation of rs4953672
is worth conducting.
5.4 Conclusion
Herein, we broadened the BVS method piMASS to work with ordinal categorical phenotype.
The approach involved extension of the method suggested by [Guan and Stephens, 2011] for
binary data to ordinal categorical response variable.
We applied the new method to the ADNI1 data set provided by Alzheimer’s Disease Neu-
roimaging Initiative, which contains 620, 901 SNP and CNV markers for 757 subjects and
contains 3 groups of patients: AD, MCI and controls. The analysis showed strong over-
lap with many markers previously discovered in other association studies, including some
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previously unknown markers.
Overall, we demonstrated the practical value of the method and its simplicity of use in
analyzing ordinal outcomes. Given relative sparsity of the methods dealing with GWAS for




In this work, we have presented various ways to improve and extend the applicability of
BVS methods for GWAS. Since the problem of GWAS is complex and depends on a lot of
factors, incorporating more features of the association between genotypes and phenotype can
make the selection of relevant genotypes more precise. We attempted to extend the genome
wide studies in two main directions. First, we want to incorporate the effects of additional
covariates into the association analysis, which can alleviate the problems such as population
stratification which are often present in large scale samples. Second, we want to extend
the applicability of BVS methods for GWAS to work with phenotypes expressed on various
scales: continuous, binary and ordinal. Those two general directions allow the existing BVS
methods reach wider applicability and potentially higher precision.
In Chapter 1, we presented the BVS methods in a context of GWAS. We discussed typical
prior setup and discussed choices that one faces when tailoring the variable selection method
to a particular problem. In particular, specifying the form of the variance of the regression
coefficients can have significant effect on the way variable selection is performed. We then fo-
cused on the theoretical foundation of the BVS method piMASS [Guan and Stephens, 2011],
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which was developed with GWAS studies in mind and has prior structure reflecting many
constraints and assumptions genome wide association studies usually face. Particular atten-
tion was given to the prior on the variance of the effect size, allowing the inclusion of many
variables with small effects, which is often the case in most GWAS. We discussed the MCMC
scheme of the piMASS, which will serve as the base for our developments in later chapters.
At the end of the chapter we provide the outline of the dissertation.
In Chapter 2, we performed the full GWAS of the MGS dataset containing genetic data on
schizophrenia patients and controls with 5334 subjects using multivariate BVS method pi-
MASS. We contrasted our results with the previous univariate analysis of the MGS dataset
[Shi et al., 2009]. We showed that piMASS can improve the power of detecting SNPs as-
sociated with schizophrenia, potentially leading to new discoveries from existing data sets
without increasing the sample size. To allow for local additive effects, we tested SNPs in
groups. We used permutation test to determine statistical significance to compare our re-
sults with univariate method. While the previous univariate analysis of the MGS dataset
revealed no genome-wide significant loci, using the same dataset we identified a single region
that exceeded the genome-wide significance. The result was replicated using an independent
Swedish Schizophrenia CaseControl Study (SSCCS) dataset. The study demonstrated the
capability of piMASS to analyze real data sets and get meaningful conclusions from the
analysis. The results of this chapter explains our motivation for using the piMASS as a base
methods for extensions provided in the next chapters.
In Chapter 3 we presented the first extension of the piMASS, which involved incorporating
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additional covariates, potentially accounting for population stratification in the variable se-
lection process for GWAS with continuous phenotype. Since current pooled genetic datasets
can contain distantly related subjects, it is possible that their relatedness can lead to false
positive associations. The ability to account for population stratification allows for more
precise association identification by decreasing the effects of possible population stratifica-
tion often present in the sample. We implemented the extension by including additional
covariates in the regression model and specifying priors on them. When identifying the as-
sociations, their effect is subtracted from the continuous phenotype, leaving the part that is
assumed to vary due to genetic effects. We provided full theoretical treatment of the problem
and specified a detailed MCMC algorithm. We performed simulation studies using both sim-
ulated and real genetic data and generated 100 phenotypes for each data type. ROC analysis
of the data sets containing simulated genetic data showed slight increase in the AUC for the
proposed method. This difference was found to be statistically significant at 5% level (p-
value = 0.01477) according to the DeLong’s test for two correlated ROC curves, which tests
if the difference in AUCs is random. The PAUC metric showed similar results with the new
method showing slight increase and statistically significant difference (p-value= 0.01249).
The ROC analysis of the datasets containing real genotypes showed similar results for AUC
(p-value= 0.002198) and PAUC (p-value= 0.002575). Both AUC and PAUC results for both
simulated and real genetic variants show that the difference between the proposed method
and piMASS is unlikely to be random. Overall, simulation studies confirmed the efficacy of
the proposed method.
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In Chapter 4 we presented the second extension, which included incorporating additional
covariates in the BVS model for GWAS with binary phenotype. Binary phenotype requires
additional layer of analysis accounting for it, which poses additional challenges. The goal of
the extension is to increase the precision of the association analysis by decreasing the effects
of population stratification. We provided theoretical framework for including additional
covariates when the phenotype is binary, which is based on the data augmentation approach
[Albert and Chib, 1993] and involved introducing latent continuous variables that serve as an
underlying response. We implemented the method and conducted simulation studies to check
its efficacy. The ROC analysis of the studies performed using data simulated using package
COSI showed the significant visible dominance of the new method. However, according to
the DeLongs test for two correlated ROC curves values of AUC showed the p-values of 9.4%,
which is above the 5% significance threshold. The results for PAUC are similar and showed
p-value of 27.18% which shows that for a specified range of specificity the performance of
the two methods is similar. Performance in simulations using real data was slightly better
with p-values for AUC and PAUC being 7.8% and 7.7%, saying that the difference is unlikely
to have occurred by chance. In this chapter we also provide real data analysis using real
dataset ADNI1 containing the 620,901 SNP and copy number variant (CNV) markers for
757 subjects (449 males, 308 females) with 3 types of Patient Diagnosis groups: Neurotypical
Controls, Minor Cognitive Impairment, Alzheimers Disease. We combined the MCI and AD
together to get binary phenotype. We successfully applied the new method to this data
and discussed the results. Overall, we demonstrated the ease of use and applicability of the
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proposed method.
Chapter 5 contains the third extension which included the BVS method that can work
for GWAS with ordinal phenotypes. Many association studies can be performed on traits
that are recorded on ordinal scale, however, there are not many methods that easily per-
mit that, especially among BVS methods. Therefore, creating a BVS methods capable
of finding associations with an ordinal outcome is useful. Here we extended the piMASS
to work with ordinal phenotype by extending the simplified data augmentation approach
[Albert and Chib, 1993] offered in [Guan and Stephens, 2011]. We then performed a real
data analysis of the data set containing genetic data and ordinal phenotype. We applied the
method to the ADNI1 dataset containing the phenotype with 3 categories: 0-Neurotypical
Controls, 1-MCI and 2-Alzheimer’s disease.
We found various previously discovered associations as well as some novel associations. The
top signal rs4953672 has not been detected in the previous studies. The third best signal
rs2075650 has been found to have significant association with Alzheimer’s disease from nu-
merous large scale GWAS and has confirmed highest association with the apolipoprotein E
(APOE ) locus. Overall, several markers were found in previous Alzheimer’s GWAS stud-
ies. We also found a group of markers (rs36258, rs939085, rs6480572, rs9641952) that are
connected to the SNPs associated with various phenotypes reflecting the cognitive function.
Such phenotypes included self reported educational attainment, mathematical ability and in-
telligence. Moreover, we found a group of markers (rs6480572, rs73485, rs883218) that were
in LD with the markers associated with various physical illnesses, not directly connected to
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the brain and its physiology. Such phenotypes included body mass index, coronary artery
disease and metabolic syndrome. Additionally, some markers (rs227918, rs4149577, rs88321)
were in LD with markers associated with other brain-related diseases such as Parkinsons dis-
ease and multiple sclerosis. Significant overlap with previous research suggests the method
works well and presence of new associations point in the direction of potential improvement
over existing methods.
There are several ways current work could be expanded and improved. One possible extension
is to develop a combination method that both accounts for additional covariates related to
population stratification and works for ordinal phenotypes. In Chapter 4 we offered a method
to account for population stratification for binary phenotypes and it is straightforward to
extend it to work with ordinary phenotypes using the approach presented in Chapter 5.
Next, accounting for correlation structure among covariates is a potential source of signifi-
cant improvement. However, computational factors should be considered when implementing
it since repetitive large scale matrix operations may serve as a limiting factor for the ap-
plicability of such method. Additionally, extending BVS method to work with unordered
categorical phenotype is another possible extension that can increase the applicability of the
method. Moreover, in this work we adopted simplified view of population stratification that
assumes that several derived covariates can account for population structure complexity. It
is possible there is a more detailed way to incorporate this into BVS.
As field of GWAS continues to develop and grow, there is more need for dedicated statistical
tools. We addressed some of the issues that arise, in particular for neuropsychiatric and
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other phenotypes, which are expressed as a categorical variable. Ultimately, we would like
to see the development of the methods that can use the information obtained from GWAS
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